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1. 1. THE SCOPE OF BIOTECHNOLOGY
Biological science is now very diversified and boasts a large
number of sub-disciplines (biochemistry. genetics. microbiology.
physiology. morphogenesis. systematics. plant and animal anatomy.
ecology. bio-physics. bio-informatics ...
). 
The practical
applications of these sciences. building on the pragmatic.
successes of the preceding centuries , are fundamental to modern
standards of food supply. health care. and more generally to
man s ability to control his environment and exploit living
organisms to produce useful goods and services. Yet in the light
of the developments of the past two decades. it is clear that
biological science still contains vast further potential to
contribute to human welfare.
The sum total of these applications. which directly support the
promotion of health care, of bio-industries and of agriculture,
may be considered to constitute the field of biotechnology. The
definition is however unsatisfactory because it lacks specificity
and because it fails to distinguish between traditional and
modern approaches to the domestication and transformation of life
(*)
on this planet. For this reason, the Commission has suggested
that the biotechnology which is relevant to the removal of
current scientific and technical barriers to the promotion of
health and the development of industry and agriculture be
designated as "new biotechnology ; it can be characterized in
terms of the scientific iJreakthroughs which are expected to
contribute significantly  hi  the solution of contemporary
problems.
(*) Framework Programme for Community  SiT  Activities 1984-1987
(COM(83)  260  final). and supporting paper: Plan by Objectiv8 :
Biotechnology (doc. XII-37!83).:hese ':I:.:'E':ik.::1n:oughs ai'e numerous and include the following
- the development of cell and enzyme technology.
chat i~ t ~ say the creation of new bio-industrial methods based
upon the Ufie of the catalytic properties of enzymes for the
t:".a.1sformatior. of raw materials and agricultural products.
- the recently acquired capacities of man 
transfer geretic i:lformation b ~t"Jeen distantly related organisms
and tc :...ns..\rt purely "synthetic information into organisms.
theTeb~' ohtaining new useful living entities.
- the promotion of molecular and cellular
approa' :he3 for the detection and treatment of pathological
conditions in living organisms.
- the improvement of techniques for the selection
and cultivation of microorganisms. animal cells and plant cells
and for the manipulation of their behaviour under controlled
conditions.
into
- the elaboration of methods for the regeneration
fertile and differentiated individuals of individual
axenically-cultured
sterile media) 
plant cells (i.e. grown and isolated
- the development downstream processing
techniques for treatment. extraction, purification and conversion
of useful materials following the stage of bio-mass production.
1.2. SIGNIFICANCE OF THE NEW BIOTECHNOLOGY
1. The applications in sight
--- - ------ - -- - --- -- - - ----
The importance of the new biotechnology has been stressed and
discussed at length in a profusion of documents prepared. since
1975 by the services of the Commission. and. more recently. by
national governments and international agencies (for a detailed
and comprehensive appraisal see COM(83) 328/2 (Background note
on biotechnology national initiatives presented at Stuttgart).
In brief. it Can be stated that some important industrial
applications (production of monoclonal antibodies. preparation
of new vaccines. synthesis of high value products including
antibiotics, amino acids. and proteins such as insulin and
interferon. and detoxification. microbial leaching for the.
mining of metal... ) exist worldwide, with the focus of currentdevelopments particularly in the USA and to a lesser extent in
Japan and Europe. Many significant achievements may be expected
before the end of the present century. The areas principally
concerned are outlined in figure 1. The advances in sight have
been described in 1980 and 1982 by the Commission services in
the proposal for a Community programme in Biomolecular
Engineering and in the FAST report. They will undoubtedly
include
- the creation. through the use of recombinant DNA
techniques, of cell lines and strains of organisms displaying
new properties (increased symbiotic capacities. disease
resistance. high protein yields
...
) or able to accomplish
functions (synthesis. conversion. concentration. fixation.
degradation) essential for the production of - food. feeds.
pharmaceuticals, chemicals and energy.
- the construction of new types of reactors for
bio-mass processing. the treatment of wastes. the recycling of
useful materials and the large-scale transformation of raw
materials into classes of compounds that can be exploited by
industry. Many of the new developments in fermentation will
depend upon the availability of enzymes and cells isolated or
produced by biochemical or genetic engineering techniques and
upon basic knowledge acquired in microbiology. informatics and
robotics.
- development of methods. more reliable and less
expensive than those used presently. for toxicological testing
and the evaluation of pharmaceutical properties; and the
development of new products through the use of "rational" and
computer-assisted design techniques.PH.A9MACEUTICALS ANIMAL HUSBANDRY
r wo~di
'- -_ ------~-
I Agricultural I
L~:..o~':..c:~ - - I
r-----
I Bio-mass' 1__- _
Microbiolo and
cell culture
G...t ic  i."d
eneration of entire  lants
AgricuLturaL. inputs and practices
Figure 1 : Biotechnology : a multidisciplinary approach to the
domestication of biological organisms. Research in
molecular pathology. fermentation and enzyme technology.
microbiology and cell culture. genetic engineering and
plant cell differentiation contributes to the development
of new. approaches. processes and products essential to some
of the requirements of man.2. Market potential
----------------
Many widely varying estimates have been made of the market
potential of biotechnology in the coming decades, questions of
. definition being a major cause of the discrepancies shown
below; but both these estimates. and the R&D and investment
behaviour maj or companies. reflect forecasts
increasing proportion of GNP attributable to products and
services of "biotechnological" nature. A rough calculation
indicates that  over 40 % of manufacturing output in a developed
industrial country is biological in nature or origin
therefore likely to be influenced or transformed
developments in biotechnology.
and
Some estimates ($) of world market potential for biotechnology
IMSWORLD
current market 1990 2000
8 bn
(*)
13bn
27bn (US only)
500
Source
T .A. Sheets
Business Communications Co. Inc.
Information Services (London)
OTA Report : products (food and pharmaceuticals 7. 4 bn
based on r-DNA technology (chemicals
Policy Research Corp.. cumulative 1980-2000, agriculture
50-100 bn
Products made by genetic engineering techniques medical
MITI, Japan
: "
Japan s biotechnology market
(Japan Economic Journal, 28 Dec. '82)
5- 10 bn
6trillion
$ 16-24 bn
(*) Breakdown by sectors of T . A. Sheets estimate
Alternative energy products 16. 3 ; new foodstuffs 12.6 ;
health care products 9. 1 ; industrial chemicals by
biotechnology 10. 5 ; agricultural chemicals 8. 5 ; copper
and nickel leaching 4. 5. Note that this omits potentially
major new sectors such as microbial enhancement' of oil
recovery.3. Company responses
-----------------
The mushrooming biotechnology companies has been most
evident and widely reported in the U. A. : by April 1981 well
. over 100 companies had been launched. with share offerings
exceeding $ 1.1. billion. Best known are Cetus (market
capitalisation $ 400 m in mid-1981, ~ 370 m. In June 1983). and
Genentech ($ 280 m in mid-1980. $ 563 m. in June 1983) of the
specifically biotechnology companies Hybritech is of similar
magnitude. The "Biofutur listing of 25 U.S. companies
specialised in biotechnology totals market capitalisation
$ 3. 2. bn in June 1983. But the major financial driving forces
are the oil. chemical and pharmaceutical groups, who are
investing heavily (see box).
Some examples of biotechnology related R&D expenditures and
investments
Dupont : ~ 150 m capital expenditure commitment in life
sciences, 1982-84. 1981 R&D expenditure in life sciences,
over $ 180 m.
. $ 67 m. (inflation-indexed) 10-year contract between Hoechst
and Massachusetts General Hospital. for molecular biology
research.
6 m agreement between Dupont and Harvard Medical School,
for research on molecular genetics.
5 m funding by Shell of Cetus ' work on human interferons
$ 40 m R&D agreement also reported.
. ~ 70 m investment by International Nickel, Schering-Plough.
Grand Metropolitan and Monsanto in a new private company
Biogen ; originally Geneva-based.
. $ 5 m participation by Dow in Collaborative Genetics.
. ~ 29.4 m acquisition by Schering-Plough of DNAX Ltd., a smal
Californian biotechnology firm.
. ~ 120 m. investment by Schering Plough for interferon
production in Ireland.Multinational companies such as Monsanto or Hoffmann La Roche
are strongly represented in Europe. and typically pursuing a
long-term oriented strategy based on four elements
. - 
development of  in-house capabilities at key
Monsanto : St.Louis ; Dupont : Wilmington;
Roche : New Jersey - i. e. mainly U. S.. even
European origin).
research contracts with specialist biotechnology companies
centres (e.g.
Hoffmann La
for firms of
(examples in box) .
research contracts with key individuals and teams in
universities.
sharing of risks and costs of long-term research and
venture" activities with firms not directly competitive
in their major sectors. by "joint research companies" - e.g.
Biogen ; or note that Cetus, although publicly quoted, is
controlled (S out of 9 directors) by the major companies
French example is Transgene, created by Paribas, Assurances
Generales, Elf Aquitaine. BSN and L' Air Liquide.
Europe s major oil, chemical and pharmaceutical firms have been
active in the development of biotechnology - e.g. ICI. BP and
Hoechst have all invested significantly, but so far
unprofitably, in single-cell protein R&D and production
facilities. Food firms have been active. where organised on an
adequate scale ; cf. the investments by Tunnel and Amylum in
the isoglucose process ; or Unilever' s development of plant
tissue culture and propagation techniques for oil palms. In
pharmaceuticals, many of Europe s companies are world leaders
and two these. NOVO (Denmark) and Gist-Brocades
(Netherlands) dominate the world market for industrial enzymes.
with shares of some 50 and 2S %, respectively.
Faced with the challenf,es of biotechnology, and with their
particular breadth in terms of the multi-disciplinary skills
required and the many market sectors potentially affected,  most
companies react nervously : they do not have all the skills
in-house. and they realise that their established areas of
strength may come under attack from an unexpected direction.7here there::ore a strong readiness to look outside for
I!Xp,.'.rt :sc.. to buy knowledge from elsewhere, seek an
"llj.aar.c '..lith. or a share in. some competent centre of knowhow
ia l-i;:J\.:f~c:rmclogy.
. Eve-:\ ~or tile European companies. the
ff elsewhere II and the
ccml)eteF: centres" have been sought in the U.S. (cf. Hoechst -
EGH a~r~ement, Dutch discussions with IPRI California, U.K. -
Japc' n"'-s~~ collaboration) while the major U.  companies with
customary thoroughness do n~t Eeglect the centres of expe~tise
in E,irope (cf . Biogen. and many direct university contacts).
It :::'s difficult tc obtain precise. reliable or comprehensive
figures. but from the reports and data available it appears
probable that the substantiall exceeding total
European Community activity
a) ia the number and scale of investment in small, new.
venture capital" companies in biotechnology (even a 90%
failure rate" may be less important than a 10% "success
rate
b) in the development of medium-sized specialist biotechnology
companies such as Cetus. Genentech, Genex. Hybritech. IPRI,
Collaborative Genetics....
c) in the capital investment and recurrent expenditure on R&D
in biotechnology by the major oil. chemical and
pharmaceutical firms ; it is possible that in agro-food, the
major European firms are being more innovative. although it
has been claimed that certain specific developments have not
been sufficiently encouraged by national regulations
or Community market regimes.
The gap is narrower if the important biotechnology capabilities
of Switzerland and the Scandinavian countries are included. In
basic research and technological capabilities. the situation is
much more evenly balanced : collaboration with Europe. and with
research centres Europe. therefore still major
in teres t to the U. S. and Japan.4. Strategic significance
----------------------
Biotechnology has engendered enormous enthusiasm shown for it
in recent years (*) . the importance attached to it by industrial
. investors and the public authorities (less by Trade Unions and
consumer associations) . being based upon the following
reasoning
it constitutes a fundamental tool of socia-economic
development.
Theorists of "long-wave" economic cycles see biotechnology
(after the new technologies of automation. information and
communication). as the driving force of basic innovation for
the next long cycle which the economy of the West is
entering. Whether or not one accepts such a theory. it is
clear that the scale of potential application (current and
long-term) within most fields of human activity makes.
biotechnology  a powerful tool for renewal and innovation of
the economic base of contemporary society . In sector-specific
terms. biotechnology. and in particular the new chemistry
awaiting discovery and exploitation within the cell. is 
of the few major sources of innovation so desperately needed
to restore the prospects of the chemi~al industry in the
industrial world. It provides an incentive and a direction
for the new accumulation of investment: capital needed to
re-establish a phase of economic growth.
Biotechnology is altering certain aspects of the
international division of labour . through increased
(*)
There have been countless special numbers on biotechnology by
the specialist scientific press. the popular science reviews. and the mass circulation press. Scientific reviews or
newsletters exclusively devoted to biotechnology have also
app.eared : e.g. Biofutur, Biotech Quarterly. Biomass. Biotech
News, Bioi technology, Biotechnology Bulletin. Biotechnology,
Industrial Biotechnology, Biotechnology Newswatch. Telegen
Reporter. Practical Biotechnology. Biotechnology News.
Bio-Engineering News , Bio-Sciences. Genetic Technology News.
Swiss Biotechnology.....cc.m,?E c~_tion between the. industries to which it is relevant
(ti.gro..foorl. petrochemicals. pharmaceuticals. environment
industry. water treatment and distribution... ). and through
reT3tr.lcturing and re-grouping at both national level and
am.)ngut the multinational firms ; the evidence is clear in
the patent applications. licence agreements and R&D
iDvest~Ents. Inte~se competition is taking place between
COlIlIUunity countries to Ca")t1!re both the expanding domestic
markets and the export markets ~ It would be misleading to
mention only the competition between Europe and the U.S. and
Europe and Japan, the more so since it is noticeable that
Eu:cop~ans often appear to prefer to collaborate with Japan
and the U. S. rather than with one another.
Biotechnology may contribute to the easing of certain
strategic constraints world scale. wnich weigh
particularly upon the countries of the Third World ; basic
health. food production and storage. nutrition. energy.
environmental problems.
The strategic significance of biotechnology (and similarly
knowledge-based11 industries) is underlined by the current
debate in U. government circles the modification of
anti-trust law applied collaborative efforts
industrial research.. 2.
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z.~:  1. The relative weight and importance of current efforts in
. '
if.,
--- -------- --- -- ---------- ------ ---------------- - - - - - ---
the Member States
-----------------
The efforts carried out throughout the world and within the
Community for the promotion of modern biotechnology have been
assessed by the FAST-group of DG XII and are outlined in
detail, country by country, in the
Biotechnology (doc. XII-37/83), which
Plan ):Jy Objective
was prepared
supporting document for the First Framework Programme for
Community SiT Activities 1984-1987, and more recently, in the
background note "National initiatives for the support of
biotechnology R  DII (COM(83) 328 final/2), prepared 
accompany document COM(83)328., "Biotechnology : the Community
role at the Stuttgart Council, 17 June 1983. From the
information available, the following conclusions can be derived
on the scope and nature of biotechnological R&D in the Member
States
2. The slo-w- emergence of modern biotechnology in European
------------------------------------------------------
countries
---------
With the exception of the Federal Republic, where industrial
strength in several applied fields of molecular biology began
to be built, as early as 1974. on the basis of a major report
prepared by DECHEMA, the signal to the Member States that
modern biological research was central to the evolution of
agriculture and industry WaS issued in 1975 in the preparatory
documents for Communi ty programme b iomo lecular
engineering. These documents were complemented. in 1977, by the
studies of D. THOMAS and A. RORSCH on enzyme technology and
genetic engineering. National reports which served as platforms
for the elaboration of strategies in biotechnological R&D inMember States appeared in 1979 in France ("Sciences de la vie
et societe" by GROS. JACOB and ROYER), in 1980 in the United
Kingdom (SPINKS report) and increasingly thereafter : over 10
national reports were published in 1981. It is therefore not
-surprising. in view of the late entry of the Member States in
the so-called biotechnology race. to note that the impact of
European R&D in bio-scilences . and in. key areas of applied
biology has been relatively weak during the period 1975-1980.
The lack of competitiveness in both basic and applied research
is illustrated by surveys on patent distribution in the
important area of enzyme immobilization (data provided, for the
period 1977-1979, by the patent department of the society SMITH
KLINE-RIT) .
3. A substantial but incomplete effort in the Member States
--------------------------------------------------------
Detailed appraisal of current R&D spending by governments and
private firms throughout the world indicates that in the Member
States of the Community, Public Authorities invested in recent
years for biotechnology approximately $ 150-350 million per
year as compared to 200-550 in the USA and at least 50 in Japan
(The wide ranges reflect the divergent definitions 
biotechnology, e. g. covering greater or lesser proportions of
agricul tural biomedical research) . Funding private
, industries was very much larger. Community firms, although
outspent on average by US and Japanese enterprises, display
very substantial strength in several instances. Illustrative
examples of this strength are to be found in the annual R&D
budgets
Hoechs t
companies such
and
as Unilever (mainly agro-food),
pharmaceuticals) , and other (chemicals
European-based giants, with R & D budgets exceeding 200 MioECU
p .
a. significant elements of this R & D being at least
biotechnology-relevant (see also 1. 2.3. above and COM
(83)-328 finalj2 : "National initiatives for the support of
biotechnology R&D"
2 . 2. EUROPEAN EFFORTS : IMPORTANT BUT FRAGMENTED
As evidenced by current deficits in trade .and in patents and by
the continual emigration of competent scientists, the efforts of
the Member States, in spite of their magnitude in financialterms, remain insufficiently productive. The lack of commercial
competitiveness in modern Europe has recently been examined in
two U. 8. studies. which independently arrived at similar
conclusions. One recently "leaked" report was prepared for the
O.ffice of Science and Technology Policy of the White House by a
working group drawn from several federal agencies. Its assessment
of the competitive situation in biotechnology bluntly concluded
The U. S . faces the stiffest challenge from Japan
On Western Europe s biotechnology
" . .. 
In general, the lack of qualified scientists and engineers
(particularly in process and purification technologies) ,
inadequate industry/university cooperation. and - belated and
insufficient R&D funding by industry and government. are probably
the biggest barriers to commercial competitiveness in these
countries. In addition, the West German and British Governments
are con~ru.ed~ 9ve.J: th~ el)ligration of scientists from their
countries, many of whom are working in the U. 
11 . . 
(Competitive and Transfer Aspects of Biotechnology;
Commercial Aspect!fs.. of Biotechnology ; Policy Option
Papers. Report delivered to George A. Keyworth.
Science Adviser to the President, 27th May 1983).
The two-year assessment the Off ice Technology
Assessment to be published in October 1983. "Biotechnology
Commercialization and International Competitiveness" states (in
the draft version of May '83) :
Japan will be the most serious competitor to the United States
in biotechnology. It has a very strong bioprocess technology base
upon which to build, and the Japanese Government has specified
biotechnology as a national priority...
The European countries trail the United States and Japan in the
commercialization of biotechnology. They are generally not as
aggressive, either industrially or through government laws and
. policies.
The lack European competitiveness res~lts from
the
serious
deficiencies and weaknesses affecting entireTRAIN IN G- RES EARCH- D EVELO PMENT - PRODU C-TION -D I STRIBUTION network
upon which modern technologies need to be based.
These deficiencies and weaknesses. which create barriers
ip.novation and the development of a large unified market for
biotechnology products in Europe, have been identified in the
FAST report and in the Plan by Objective : Biotechnology. They
can be ascribed scale and structural factors which are.
themselves, the direct consequences fragmentation into
isolated national policies.
1. Scale factors : the failure to achieve "critical mass
------------------------------------------------------
The traditional applications of biology to industry and to
agriculture have been developed over long perfods of time,
through sporadic progress within isolated disciplines.
The connections between basic science and technology were not,
the pas t. intimate they are now, and the R&D
requirements for significant progress were relatively limited,
remaining within the scope of individual nations at the
limit, restricted to the work of a few imaginative scientists
able reproduce industrial scale the experimental
conditions under which they had controlled transformation
processes in the laboratory. It was during this period that
European countries. exploiting a research base built up slowly
over a long period of time. and developed more rapidly over
recent decades. organized strong national capacities for the
processing of foods, chemicals and pharmaceuticals..
The sudden advent of modern biotechnology. with its
multidisciplinary complexity, its relatively high investment
costs and the rapidity of its evolution in the USA and Japan
now demands a scale of effort at all stages from applied
research through development to industrial exploitation. which
is beyond the resources typically available within individual
Member States within the European Community. This weakness.
less salient in the case of fundamental research. where Europe
maintains a firm traditional strength through the coordination
work of EMBO, ESF and other scientific organizations. is more
pronounced
development.
basic biotechnology and industrialIn  basic biotechnology that is to say in the portion of
research located half-way between the fundamental study of life
and the industrial exploitation of its properties and
mechanisms, the insufficiencies of the Community derive in part
. from the dispersion and isolation of national efforts.
The problems being tackled are, in many cases, at the stage
where we are sure we can solve them soon - in one way or
another. But we must, community keep in play many
parallel but different attempts at a solution until one gains
in competition over the rest. (The classic example is the
European Organisation for Research on the Treatment of Cancer
EORTC) .
This can only be done by organised concertation across a very
wide technology base - i. e. that of the whole Community (and
this implies organised Euro-wide groups of  needers . potential
clients, as well as conce~tation on the supply side of
problem-solving) .
Even the larger Member States, if they work in isolation, may
have difficulties. for any given scientific or technical
problem, in providing the national industry with the wide range
of potentially relevant solutions which need to be tested
within short periods of time for rapid innovation and conquest
of the market. Similarly, with the exception of a few major
European firms. hardly any industry in the Mernber States is
sufficiently diversified to explore the application of new
discoveries by testing them simultaneously against a wide range
of different problems. Lack of concertation of national
research policies in basic biotechnology and the isolated
manner through which they are implemented accounts. in addition
to duplication which can be useful in effect. for gaps in
research capacities. Several areas industrial
microbiology. agricultural genetics and enzyme technology,
suffer from the absence in each Member State considered
separately of sufficient high-level expertise and know-how for
undertaking on a systematic basis the analysis and control of
the most complex molecular mechanisms and biological functions
upon which the biotechnology of tomorrow will establish its
foundations. The fact that several European biologists ofoutstanding ability have hired their services to US firms is.
moreover. a clear indication of a lack of mobilization within
the Member States and of the incapacity of a single country.
even as large as the United States. to depend entirely upon its
.own scientific resources.
Significant weaknesses can also be found in the  developmental
capacity of European industries where innovation. except for a
few large-sized commercial enterprises, is usually
insufficient. The inertia of industrial R&D activities
greatest in areas where the short term commercial incentives
are insufficient. This is particularly the case in the health
industry where the strong trend for replacement of the private
customer by the state customer has revealed the need for a
reorientation of R&D leading to the production of new drugs for
the prevention and/or rapid treatment of widespread "expensive
diseases and for cheaper. more reliable,  in vivo non-invasive
tests and for in vitro methods for pharmacological and
toxicological testing. Similarly. the ever-increasing problems
faced by the Common Agricultural Policy and their effects on
the prices of industrial feedstocks have underlined the
necessity for large scale developmental efforts conciliating
the needs and interests of both agriculture and industry.
2. Structural factors : the absence of a favourable context.
- -- - ------ -------- - --- ---- ---- ------- ---- ------- -- -------
Because the decisive importance of applied biology was neither
recognized immediately by the Member States nor considered by
them as a justification for collaboration and concertation at
Community level. biotechnology in Europe lacks the supportive
context which is necessary for its expansion. The absence of an
appropriate environment can be strongly perceived in those
areas where  basic biotechnology needs to be promoted and
industrial competitiveness established.
Research in basic biotechnology cannot be properly implemented
in the absence of an appropriate logistic support (data banks.
biotic collections. patent counselling. multidisciplinary
training
. . .
) for laboratories. The efficiency of such support
depends directly upon the scale of market they serve and the
total resources and abilities contributing to the support
facilities. Within the Community. these resources and skillsace gtmerally dispersed or grouped on a national basis on too
snail ~ 8cale in proportion to the importance of the research
z:ot:.:em ~.nd to the supportive context from which laboratories
if. t :m ~SA or Japan are able to benefit. With the exception of
f~w ~~ce~t and still restricted initiatives from the
Comm:::"ssior: services. no attempt has yet been made to provide.
b~sj c biotechnology research with the supportive context which
EUBO t.as :,0 3uccesdfully established for fundamental research
in mole::ular biology.
The proiD.otion of inJustrial and agricultural competitiveness
a ve~y raFidly evolving area like modern biotechnology depends
to a large extent upon clear and well adapted regulatory
regimes at all stages from laboratory development and testing
through marketing to post-marketing monitoring. There is, in
the Community. an obvious conflict between these regimes,
national in concept and in scope. and the Community market,
continental in its dimensions and structures. Examples of the
unsuitability of the general frame within which European
biotechnology is presently compelled to develop are numerous.
They range from the prohibitive prices of certain raw material
resources needed by European transformation industries, to the
adopt.ion of regimes which are contrary to the development of a
European strength in biotechnology. The production of single
cell protein (SCP) constitutes, in this connexion. an
interesting example of a biotechnological venture which was
halted by regulatory and acceptability problems in one country.
3. THE NEED FOR A COMMUNITY APPROACH : THREE STRATEGIC AREAS
As emphasized above, in section 2. 1, the weaknesses of the Member
States in modern biotechnology can be ascribed, ultimately. to 
- the failure to achieve "critical mass" in research capacity.
which European companies often attempt to reach through mergers
or joint agreements with U. S. and Japanese firms.
lack of action in certain key areas where urgent Community
needs have been identified addition of greater value to
agricultural products, adequate supply to industry of raw
materials of agricultural origin, reorientation of the R&D ofhealth industries. adaptation of industrial.
intellectual property systems.
- lack of a supportive cOntext for research, development and
industrial exploitation related to the dimensions of the
European market. The current rules and regulations established
at national level considerably hamper, and sometimes prevent,
commercial and
the possibility of market unification at Community scale.
In addition. one must also underline the state of neglect which
is presently characterizing biotechnology in Third World
countries. The applications of modern biology do offer solutions
to nutrition, health and agricultural development problems in
several parts of Africa. Asia and South-America. As yet, however,
no great attention has been given to this potential in the
promotion of agricultural and medical research conducted in the
developing countries.
The Community Development Policy, as outlined in the
September 1982 memorandum from the Commission to Parliament and
Council (*) envisages a significant role for biotechnology-
related activities : as reflected both in the current programme
of Science and Tech~ology for Development (**) and in the
proposals currently being debated for a science and technology
(***)
programme within the developing countries
obvious. stressed section 2. . that these
deficiencies essentially result from the. fragmentation of
biotechnology R&D in the Community and that they will not be
overcome without
(*) 
COM(82) 640
(**) 
COM(81) 212
(***) COM(83) 3541. 1he e~t~~li8hment of strong Community foundations in basic
- -----.- -- -.. -------.-----------.------------------.-----------
bi.ot~C'.h' lo~l:Jgy
----..-- ...----
It i~ f~Cill su~h foundations that European industry and European
a:~ri culture. now very closely related and interdependent, will
be p rovidf d with the wide range of different solutions against
which a wide range of d: fferent problems may be tested
simulta~eoasly with the maximum rapidity and minimum of
eJ!:pense. fpecific ~kills and competences, industrial know-how
and appropriate research facilities do exist at several sites
within the Community but the present efforts. carried out at
national level. are dispersed and lack the coherence and
efficiency which can result only from the mobilization of
potentialities within the Community. The Member States need a
strong Community nucleus of expertise to serve as a driving
force for systematic and coordinated implementation
mission-oriented research in basic biotechnology. The action to
be undertaken is considerable and involves, through
multidisciplinary training and research, the transfer of
academic knowledge to industry and agriculture and the removal
by multiple solution-problem testing approaches of technical
bottlenecks to large scale applications.
2. The stimulation of specific industrial R&D
---- ---- ------------- -- ----- ----- ------ ---
Although
European
the relatively large investments now agreed by
industries in biotechnology and the confidential
nature these activities render unnecessary and even
inopportune a direct stimulation through massive Community
funding of industrial R&D. there are still two domains where
specific Community incentives appear to be urgently required.
1. A need for European feedstocks of agricultural origin.
... .............. ......... ........... ..... ... .........
In the firs.t of these domains, half-way between industry and
agriculture. there is, as stressed in the FAST report and in
the "Plan by objective : biotechnology , an obvious necessity
to provide the industries of the Member States withEuropean-grown feedstocks of agricultural origin which
harmoniously combine the industrial requirements for quality
and price with the maintenance of agricultural productivity.
Such a goal. a prerequisite to the competitiveness of
Eu.ropean industries and to the stability of the Common
Agricultural Policy, will not be reached without specific
research for extending the properties of the plant species
presently exploited in Europe and for designing new crops
adapted to the modern needs of transformation industries. The
research in plant physiology. genetic engineering.
technological design of new crops and land assessment which
needs to be executed in this area has up to now been largely
restricted to the national scale ; the European dimensions of
the problem clearly
level.
call for an initiative Community
Such developments will also respond to the longer-term global
challenges of possible shifts in the patterns of land-use.
If, for example. the strategic objective of greater food
self-sufficiency is approached in many developing countries.
this would accentuate the tendency in Western Europe and
North America to withdraw land from food production. and
increase the need re-direct towards other useful
outputs.
2. New drugs and new testing methods.
..... ............... ...... ........
The second domain is that of the health industry where. as
underlined in section 2. 2.. the increasing costs of medical
care and the replacement of the "private customer" by the
state-customer" render necessary a new orientation of R&D
strategies. There is now a pressing need for the prevention
or rapid treatment of "common and expensive diseases" and for
efficient "structure-function approaches to the routine
screening of compounds for pharmacological or toxicological
activities. These actions are particularly important for the
public interest. The discovery of new preventive or more
rapid therapeutic approaches to illness could possibly reduce
the financial burden of social security in the Member States.
The development of new  in vitro . testing methods. although itwill nev~r replace completely the present  in vivo procedures.
could nevert~~lesa provide (together with new non-invasive 
vivo testing methods) a very attractive solution for the
rapid and accurate detection of the activities of new
compounds. The establishment such methods and their
standardization throughout Europe could facilitate the
setting of unified norms and regulations within the Community
(see 4. 2. below) which would meet the criterion of simplicity
requested by health industries; conversely, the existence of
a harmonised Community market will provide greater incentive
for the development of such methods.
While the development and standardisation of tests are of
great interest to the pharmaceutical industry, it 
difficult under normal commercial criteria for firms
invest the long-term and expensive work required,
uncertain as to whether or not the outcome will be generally
and officially accepted. Such development should therefore be
undertaken by the Community as a whole since the benefits
will be felt by the whole Community.
3. A supportive context for biotechnology
.......................... ........ ....
The reasoning in favour of creating a supportive context for
biotechnology research at Community level has been presented
above in paragraph 2. 1. I  is essentially based upon
considerations of mass-efficiency relationships which show that
the pooling of logistic facilities. such as data banks. biotic
collections and training resources. will be beneficial to the
Member States because biotechnology is multidisciplinary in its
approach, complex (and therefore expensive) in its requirements
and rapid in its evolution. The requirements of modern
biotechnology in skills. materials and information (even in the
case of published data) are so large that new approaches have
to be devised and implemented at Community scale. The list of
contextual measures to be taken in support of biotechnology
research is provided in section 4.
The reasoning in favour of developing a supportive context for
the industrial and commercial expansion of biotechnology at
Community level has been presented above in section 2. 2. It hasstressed the ne.ed to facilitate access by bio-industries to raw
materials of agricultural origin and to harmonize the regimes
which regulate innovation, intellectual property. production
and commercialization of bio-products and bio-processes : only
in this way can be created the true Common Market which is the
primary economic necessity.
The actions taken each these areas are
multidisciplinary, multiple in their applications and complex
in their requirements from both the private and the public
sector. As outlined by the Commission at the European Coun~il
of Stuttgart and stressed in section 2.3., they require a
pooling of skills. a harmonization of legislation and
procedures and common decisions on prices and policies which
cannot be achieved without strong and coherent initiatives from
the Community. The effort considered necessary is presented in
section 4.ACTIONS CURRENTLY CARRIED OUT AT COMMUNITY LEVEL : NECESSITY
FOR THEIR EXPANSION
THE RANGE OF COMMUNITY ACTIVITIES
1 Research programmes with a component in biotechnology or
in applied life science
1. 2 Activities related to the harmonisation of standards and
regulations and for the assessment and prevention of
bio-hazards
THE nIOMOLECULAR ENGINEERING PROGRAMME (1982-86)
THE NEED FOR AN EXPANSION OF COMMUNITY ACTIVITIESACTIONS CURRENTLY CARRIED OUT AT COMMUNITY LEVEL : NECESSITY
FOR THEIR EXPANSION
The arguments of section 2. underlined the necessity for
Community actions in several areas of biotechnology. The
present section lists the few activities at present implemented
by the Commission which display relationships with
biotechnology R&D. This inventory is followed by considerations
on the insufficiency of these activities.
3 . 1. THE RANGE OF COMMUNITY ACTIVITIES
The Community has acquired research programmes conca~n~ng
aspec ts of life-science and biotechnology in a gradual manner.
This reflects the range and pervasiveness of biotechnology
across the various areas of responsibility of the Commission,
and the fact that the various programmes have been individually
approved. each for specific reasons. rather than having been
conceived as elements of any more embracing plan for
biotechnology research. The biotechnological component in these
programmes is often small and incidental or. when directly
supportive of biotechnology (Biomolecular
Programme). limited in scope and budget.
Engineering
These activities cover
l. Research programmes with a component in biotechnology or in
--- - - -- -------- - --- --- ------ - --- - ---- ------- --- --- -- --- ----
applied life sciences
---- ---- -------------
. Research Action Programme (RAP) "Materials
" :
includes wood as raw material in the sub-program:me "Renewable
raw materials
. RAP "Environment" : one of its sub-programmes
provides for fermentation and hydrolysis of organic wastes.
RAP "Health and safety the sub-programme
Radiation Protection" contributes much more abundantly than isg~nerally kLown  to  the basic research in enzymology and in cell
culture work upon which the foundations of modern methods in
g~nu\:ic e:ng::neering Vlere built.
. RAP "Non-nuclear energies" : two proj ects of the
sub-pro~ro:tm:!le
r;~srectively .
solar energy
on bio-mass as a
research" concentrate.
source energy and
photoJbiolc gy .
Agricultural Research Programme proj ects
implemented in the 1979-83 programme cover land use and rural
development. mediterranean agriculture. treatment
from intensive agriculture. animal pathology.
wastes
livestock
productivity, biological pesticides, plant .improvement. outlets
for products in surplus. tree diseases, enhanced production of
vegetable proteins; the third (1984-88) programme is now being
launched.
. COST (*) actions : where information is shared
with non-member countries specific research ac tivities,
including sewage sludge treatment and disposal methods,
studies of single cell protein. early weaning of piglets, plant
tissue culture, derivation of animal feedstuffs from
ligno-cellulose. food processing. amongst other subjects
. Databanks and communication networks : such as
EURONET-DIANE and its hosts. arising from Community programmes
on information and documentation in science and technology
which help many areas of life sciences and applied biology to
develop their information bases.
(*) COST : European co-operation in the field of scientific and
technical research. COST constitutes a framework for co-operation,
through concerted actions, between the European Community and
European non-Member States in the field of research and
development.2. Activities related to the harmonisation of standards and
----- -- ------- --- -- - - ----- -------- -- --- -- -- -- -----------
E~~~!~  ~!~~!- ~~~- f~E- ~h~_
~!! ~!! ~~ ~ ~_~~~_
~E~Y~~~! ~~-~ f
bio-hazards.
-----------
Several actions of the CEC in this connection, are related to
biotechnology. The Commission responsibilities
harmonization of standards and regulations require,
instance. the consideration of products. processes
for
for
and
terminology in industries such as animal rearing. food
processing and pharmaceuticals. It is in the framework of such
activities that the study of K. SARGEANT and C . G. T. EVANS on
the "Hazards involved in the industrial use of microorganisms
was issued in 1979 and that the services of the Commission
prepared a recommendation on the registration of recombinant
DNA which Council adopted in June 1982.
The Community s regulatory role in relation to the development
of biotechnology is discussed in further detail in 4. 4 below.
THE BIOMOLECULAR ENGINEERING PROGRAMME (1982-1986)
The only Commission programme really central to biotechnology
is. as mentioned above. the Biomolecular Engineering Programme.
adopted by Council in Dccember 1981 after several years of
discussions in the various committees which advise the
Commission and Council.
The general goals of this programme, elaborated after extensive
consultation with more than 200 national experts in the Member
States and discussion with leading representatives of European
industries. are to promote and stimulate the development of new
technologies leading to :
the manufacture
bio-industrial products
improved agricultural and
the determination of more efficient and safer
production methods.
Such objectives are to be achieved. in this programme. through
the removal of the bottlenecks which prevent applications to
industry and agriculture of modern biochemistry and molecular
genetics.Thta programme consists of two distinct phases. The first phase.
TlO'W 1.1 itr.plementation with a budget of 8 MioECU. includes
tra !..ni ig and research components. Training covers all areas of
bioUlclecular engineering as well as the improvement of risk
. assess~ent methoda in biotechnology. To date 20 training
contra.::t.=; have b:~;1 concluded with -well qualified scientists
HhG h iV, now started specific research activities
host-ifistitutions selected among the best laboratories
Europe. contrast with training. the research actions.
implem,mted by means of cost-shared contracts, are restricted
to safety and to the applications of biomolecular engineering
to agriculture afid to agro-food production. The call for
tenders issued by the Commission stimulated a very
large response from national laboratories in the Member States
and 180 high quality applications were received by the services
of the Commission. The resources available restricted to 50 the
number research contracts finally concluded with the
applicants. Research activities at present executed in the
framework of these contracts include
Development of 2nd generation bio-reactors
(multienzymatic. multiphasic or co-factor requiring) for
agro-food industries.
Improved and safer production. means
biomolecular engineering methods. substances important for
animal husbandry (vaccines, ... ) and for agro-food industries.
Upgrading of plant products. particularly
ligno-cellulose. by means of biomolecular engineering methods.Development of methods (and. in particular. of
host-vector systems) for the identification. transfer.
expression and transmission of new genetic information in
cultivated plant species.
. Improvement. by means of genetic engineering, of
symbiotic relationships between cultivated plant species and
microorganisms in the soil.
. Development of methods which render possible the
selective screening of cells and protoplasts and their
regeneration into fertile and differentiated plants.
A proposal for the second phase (7 MioEcu) has been. presented
to Council in June 1983. to consolidate the above work.THE NEED FOR AN EXPANSION OF COMMUNITY ACTIVITIES
The Community activities relating to biotechnology reviewed
above have not the resources to cover in depth the .three
. strategic areas identified for Community action in section 2.
instances. with the development basic some
biotechnologies through training and research. small nuclei of
European skills have been created in the framework of current
Community These nuclei (second-generation Programmes.
bio-reactors. animal vaccines. upgrading of ligno-cellulose,
host-vector systems for plant cells. plant cell regeneration,
improvement of symbiosis) are however too small in size (*) and
number.
While some international organisations exist which provide
support for basic research (European Science Foundation,
European Molecular Biology Organisation) , there is 
equivalent support for basic technological development in the
life sciences. A similar concern in the U. S. inspires current
debate on the creation of a "National Technology Foundation
to complement the work of the National Science Foundation.
(*) .
The group on "vaccines" for instance. which at the moment
includes only four contracting laboratories, concentrates upon
one major disease and is therefore unable to ensure a
comprehensive coverage of the sector. The same holds true for
the other groups where the number of contractants are 5
(symbiosis). 9 (ligno-cellulose). 11 (bioreactors) and 16 (host
vector systems).Significant action could easily have been implemented in this
area of basic biotechnology if more substantial means had been
provided to the ongoing programme in Biomolecular Engineering.
From a consideration of the number of high quality of research
proposals received, the number selected and the ratio of
support granted to each laboratory in relation to that
requested it can be shown that the Commission funded in the
Biomolecular Engineering Programme less than 10 % of the needs
expressed by the laboratories; even within the areas carefully
selected for support, there was concern at the risk that in
these areas the effort was only just achieving the necessary
minimum. It can therefore be concluded that the scientific
capacities for a significant Community action in biomolecular
engineering do exist and that the primary limitations, from a
quantitative (size of research nuclei) and a qualitative
(number of research nuclei) point of view, were of budgetary
nature.
With regard to the other areas defined for Community
biotechnology in section 2. (establishment of the factors
necessary for the development of Community biotechnology
support for Community policies in the agricultural and health
industries by specific R&D projects the promotion of
biotechnology in Third World countries) very few specific
actions have been or are being conducted at Community level.
However. worthwhile initiatives have been started recently in
relation to the development of European databanks and
information systems. for biotic materials. biologically active
macromolecules, and other information support for
biotechnology, within the framework of the 3rd Action Plan
(1981-83) for Information and Documentation. These activities
are all quite specific. having been chosen not only for their
relevance for biotechnology. but also for their suitability for
joint development at Community level. Their scope is still
quite small in relation to the total effort needed in Europe
for the promotion of competitiveness in modern biot.echnology,
and ttey ",:.11 have to be expanded
progressively, as new needs are identified.
and supplementedPRIORITIES FOR COMMUNITY ACTIONS IN BIOTECHNOLOGY
RESEARCH AND TRAINING
Horizontal Activities
1 Contextual (infrastructure) measures for R & D
-------- -- ------- - ---------- ----- -- -- -- -------
1.1.1
1.1.2
Bio-informatics
Culture collections and gene banks
2 Basic biotechnology
-------------------
1 Programme obj ectives
1.2. . Proposed projects
Specific activities
3 Agro-food and chemical industries
------ -- -- ---- --------- --- ---- --
4 Health industry
---------------
1 Pharmaceutical screening and tests
4. 1 . 2 Health expenditures and new technologies
CREATING A FAVOURABLE CONTEXT FOR BIOTECHNOLOGY IN EUROPE
1 The administrative challenge : the need for concertation
--------------------------------------------------------
2 Provision of raw materials of agricultural origin for
---- --------- ---- --- ---  --- --- -- - -- - - - - -- - - -------- --
industry
--------
1 Background : raw material needs. evolution and
problems of the current Community regime
2 Community action : ne~ regimes for starch and
sugar for industrial useA European approach to intellectual property rights in
---------- - --- ------------------------------- ----- - ---
biotechnology
-------------
1 The intellectual property problem in
biotechnology
2 Specific actions at Community level
4 A European approach to regulations affecting
------------- ------ ----------- -------- ------
biotechnology
-------------
1 Biological safety
2 Food innovation: industry. consumer and
regulator
2 . 3 Laboratory research
4 Industrial processes
5 The regulation of products and their free
circulation
RETURNS TO BE EXPECTED FROM THE PROPOSED ACTIONS
From research and training
- - ----- -- --------- - -------
1.1 Benefits from horizontal actions training
and mobility scientists
1.2 Benefits from horizontal" actions basic
biotechnology and contextual R & D
1.3 Benefits from "specific" research actions
increased added value of agricultural production
1.4 Benefits from "specific" research actions
development of new methods for the production of
pharmaceuticals, new medical technologies.
screening and testsCr2ation of conditions favourable for biotechnology
----- -------------------- ---------------------- -----
1 Benefits from providing competitively-priced raw
materials from Coromunityagriculture to industry
2 Benefits from a coordinated Community approach
on intellectual property rights and regulatory
harmonisation
4. i. 2. 3 Benefits from assessment. concertation and
networksPRIORITIES FOR COMMUNITY ACTIONS IN BIOTECHNOLOGY
RESEARCH AND TRAINING
The progralllme. detailed below. for research and training in
biotechnology follows the recommendations of FAST and takes
into account the experience acquired during the
implementation of the first phase of the Biomolecular
Engineering Programme. It was established after intensive
consultation of national experts and representatives of
European indus tries.
Its content is in agreement with the specific objectives for
R & D in the field of biotechnology as defined in the Framework
Programme for Community SIT Activities 1984-1987 (*) . These
(**)
objectives have been recently approved by Council
It is subdivided, on the basis of the Community needs
identified in section 2. into horizontal and specific actions.
Horizontal actions are always precompetitive and bear on all
branches of modern biotechnology. Their obj ective is the
establishment of a supportive background for biotechnology
research in Europe and the promotion of basic biotechnology,
thus contributing to the elimination of barriers (technical
bottlenecks, obstacles to the transfer of information.
materials and know-how) which prevent the exploitation by
industry and agriculture of the fundamental advances made by
modern biology.
(*) COM(83) 260 final
(**) Council Resolution of 25 July 1983 (0.J. C 208/1)Specific actions are designed for stimulating in depth certain
specific developments in well-defined sectors of biotechnology
which relate directly to important sectoral policies of the
Community. Their objectives are focused upon:
the development of new industries utilising
European feedstock of agricultural origin.
...;. 
the containment of costs for health care and the
stimulation of health industries through the development of new
products.
All research activities, horizontal or specific, foreseen in
the programme are to be implemented by means of cost-shared
research contracts concluded between the Commission and
laboratories located within the Community.
In .addition, two COST activities (Aquatic primary biomass
marine macroalgae and Plant  in vitro culture) which relate to
the objectives of the programme are to be developed as in
association with the general actions described below.
Other activities of cooperation with non-Member States are also
envisaged in the framework of the programme (in preparation) of
the working group on Technology, Growth and Employment which
was established by the heads of States and Governments at the
Versailles summit of June 1982.
Horizontal activities
1. Contextual (infrastructure) meaSures for R& D
-- -- ----- ---- - - ------- -- -- --- -- ----- ------ -- --
The measures presented below are restricted to the requirements
for the development of a strong research base for biotechnology
within the Community.
Other measures aiming the establishment suitable
context for the expansion of European industry and the increase
of its competitiveness are proposed in section 4.2. Reference
is to be made for training and safety to the sub-programme
Basic Biotechnology (section 4. 2). The contextual measures
proposed to develop supportive infrastructure for biotechnology
R & D can be grouped in two categories : bia-informatics and
collection of biotic materials.1 Bio-informatics
............... 
As has been pointed out by Manfred Eigen  the limiting
factor in life sciences research and application is neither
energy (as with particle physics), nor distance, nor
. materials : but  complexity . or the organised  information which
describes it.
The rate of development and exploitation of biotechnology will
become increasingly dependent upon advances in technologies of
data capture. information processing, storage and retrieval,
and upon the arrangements by which the
data are made available to potential users.
important areas there is scope and need for
Among a number of
- development work in applying recent developments in physics
and biochemistry (e.g. the various spectrometries, sequencing
techniques, dimensional gel electrophoresis, enzyme
electrodes) to the data capture needs of biotechnology
- the organization of data banks for scanning and retrieving
details of all levels of biotic material and its biological
properties (especially nucleic
crystallographic co-ordinates,
acid and protein sequences,
functional characteristics.
structural information e.g. of active sites or receptors ; and
the information held in cell and culture collections) 
- the development and pooling of experience with mathematical
models of structure, function and dynamics at all levels : from
macro-molecular (bio-physics) and cellular sub-systems
(metabolic cycles ~ membrane function). to reactor contents (as
basis for automatic control systems) 
- and the development of sophisticated interactive software
(particularly molecular graphics and "expert systems , as steps
topards "computer-aided design in biology e.g. protein
engineering - and more incisive planning and interpretation of
experiments, e.g. in genetic engineering and the more
efficient extraction and processing of results produced by
biological experiments. through professionally developed image
analysis software.
(*)
Speech at European Molecular Biology Laboratory, Heidelberg.
19 March 1982.These are all specialis.t areas. of fundamental importance and
high cost. in which the case for coordination and/or support at
European scale is powerful. The European lag behind U.
federally-financed activities is particularly significant in
computer graphics and the use of "artificial intelligence" in
life sciences research.
2 Culture collections and gene banks
........ ............. ...... .......
This applies also the collections biotic materials
themselves : microorganisms. plant and animal cell lines and
tissues, their viruses and plasmids. There are related research
needs on cell culture and tissue storage (e. g. cryopreservation)
and propagation techniques. There is no public depository in
Europe for animal and plant cell lines the case for
international collaboration has to be explored in depth.
possibly on the lines of the extensive arrangements already in
place for gene banks of plant genetic resources (seeds and
other propagules) . starting develop for culture
colle.ctions of microorganisms.
Needs have been assessed through specific studies, through the
Commission experience of collaboration with European and
international bodies (EUCARPIA, the European Association of
Plant Breeders the International Board for Plant Genetic
Resources ; the Food and Agriculture Organisation). and through
the Task Force for Biotechnology Information. an advisory group
of Member State representatives.
2 Basic biotechnology
-------------------
1 Programme obj ective
...................
This part of the programme represents the continuation of the
present Biomolecular Engineering Programme. The main objectives
are not to be modified and continue to be focused upon what is
certainly the basic priority in modern biotechnology. namely,
the removal of bottlenecks which prevent the applications of
modern genetic and biochemical methods to industry and
agriculture . The research efforts will thus be concentrated, as
in the present Biomolecular Englneering Programme, upon the
development of the second generation of enzyme reactors , thatis to say the exploitation of complex enzymatic r.eactions for
the synthesis of elaborated new industrial products, and upon
the rovement technical knowledge which aims the
directed transfer and ex ression of foreign genes and the
modification the enetic erties commercially
important organisms
However, developing and supporting this advanced front of
research is not sufficient if one recognizes that the central
problem is to domesticate and exploit as efficiently as
possible. for the benefit of agriculture and industry, the
basic properties of microorganisms. cultured cells, animals and
higher plants. In that case, basic long term research efforts
must be organized, concentrating on the detailed analysis of
the molecular genetics, enzymology, biochemistry and physiology
of those metabolic functions which man needs to control in
order to increase the performance and stability of bio-systems.
The Commission proposes include, the present
Biomolecular Engineering Programme, two projects for the
training of European scientists and for the promotion of
safety. The training action, in view of the fact that
biomolecular
biotechnology.
engineering
represents
conditions the evolution
essential element the
programme. It will cover key areas in basic biotechnology which
are still insufficiently explored and should provide European
scientists with adequate possibilities for mobility and the
improvement of skills and knowledge. The Commission will also
study manpower needs in the Community for skilled technicians
in biotechnology applications and will consider the need for
further proposals in this area.
With regard to safety the proposed programme is to concentrate
on the improvement of methods for the assessment of risks
possibly associated with the
biotechnology. The establishment
development of
of such methods
modern
the
prerequisite to any further action which the Commission may
consider necessary for ensuring the continuance high
standards of safety for workers in biotechnology and for the
general population.1.2. 2 Proposed projects
.................
The projects to be implemented are the following
- Development and evaluation of bio-reactors (and
particularly those which are multienzYmatic. multiphasic or
co-factor requiring) for industrial applications. depollution
and detoxification.
Modifications enzyme properties. protein
design. synthesis of artificial en2:ymesand development of new
methods for large scale and highly selective separation of
proteins and other substances with industrial or agricultural
value.
Development of genetic engineering, enzymes and all process engineering methods
substances (food. intermediates
for
for
the production
chemica syntheses,
vaccines, hormones... ) with industrial or agricultural value
and for the upgrading
ligno-cellulose) .
Improvement of organisms by means of genetic
engineering of the basic properties, including symbiosis, of
microorganisms, cultured cells. animals and plants which play
an important role in agriculture and industry. The actions to
be stimulated include the characterization of the structure and
plant products (particularly
expression of microbial. animal and plant genomes. the study of
the molecular mechanisms of interactions between plants and
microorganisms, the development of methods for the identification. transfer and expression of new genetic
information and the control of plant cell regeneration into
mature organisms.
- Biochemical genetics. enzymology and physiology
of the basic functions and properties of species which are
essential to the promotion of
organisms to be studied will
modern biotechnology. The list of
include the microorganisms which
indus trial use. chemo-autotrophs.
are most promising for future
methanotrophs. mycorrhiza, and representative species
families important to agriculture and feedstock production.
- Research on continuous cultures containing more
than one organism in order to gain an understanding of their
efficiency and stability as a basis for the 
industrial use of
mixed populations.- Research on factors affecting the stability of
organisms under long-term continuous cultivation and 
immobilized systems. particularly in relation to the expression
of genes contained on plasmids.
Developing micto-analytical methods for the
identification and quantitation of biologically important
macromolecules.
Development of new methods for detecting
contamination and for the assessment of possible risks
associated with applications in industry (particularly during
downstream processing) and agriculture of biomolecular
engineering.
Training of
above-listed projects.
scientists in all fields of the
Specific activities
3. Agro-food and chemical industries
------ - - --- -- -- ----- --- ------- ---
The relatively
agriculture and
independent planning
of the food. animal
and
feed
evolution
and chemical
industries could be tolerated in Europe before the rise of
modern biotechnology. at a time when the speed and scale of
technological change allowed gradual mutual adjustment where
necessary . Now, with the acceleration of scientific progress
and the suddenly increased potential for interacting changes.
there is a greater need to establish in the Community. between
agriculture and these industries. adequate channels for
continuous concertation to promote a growing interdependence.
which should result from the increasing opportunities for
cross-fertilisation of research between them. To improve
competitiveness within this whole
actions must be implemented.
sector. several research
European agriculture has improved its efficiency so much since
the CAP was instituted that some products (milk. cereals.
sugar, grapes... ) are now in substantial surplus. though others
that are more difficult to produce in Europe (wood. vegetable
proteins and oils... are still in major deficit. The
Commission s proposals in document COM(83) 500 indicate how the
market situation could be improved. Further actions to beSllppOI ted under this section seek to develop new crops (e. g.
f~st-Ervy':tng treea. better oil seeds) and new markets (e.g.
supply 1f feedstock for chemicals) through building a closer
rela~iovshtp betweea agriculture on the one hand and the animal
rf'.p.d. ft'od and chemical industries on the other.
'I~e J.inks b~tween agriculture and these industries have been
grow~n3 ~a?idly in recent years. Thus sucrose production from
Europe~n beet is becoming ever more efficient because of
integ-ra.:ed developn,ents linking improved seed. cultivation.
harvesting and processing : yet suCrose faces challenges in
various markets from sugars derived from starch and from
non-carbohydrate sweeteners. Again soya bean meal. the most
important protein-rich animal feed supplement. now faces some
competition from colza meal derived from newly developed
strains of European grown colza and rrom newly developed single
cell protein produced by European chemical industry. These
developing links are what make it unwise to treat agriculture
and the animal reed. rood and chemical industries in isolation.
In recognition or th;ls the Commission has already decided to
adjust the system in rorce for supplying agricultural raw
materials for non-rood use in the chemical industry so as to
ensure that the Community industry benef:its from the same
conditions of competition as its outside rivals 
(*)
The European chemical industry was developed rapidly after
World War II with the benefit of secure and inexpensive
supplies of petroleum from the Middle East. Today. though it is
somewhat less dependent on external supplies of petroleum that
it was. these external supplies are both less secure and more
costly than they were. At the same time. the industry races
challenge, particularly from bulk chemicals made in new plants
built near to abundant petroleum sources. What are the
prospects for basing European chemistry on agricultural
feedstocks FAST study by Gibbs and Greenhalgh.
Biotechnology in the Production of Chemical Feedstocks and
(*) COM(83) 328 final.Derived Products concluded that while proposals to supply
heavy chemical feedstock from European agricultural raw
materials are not credible. the prospects for producing some
materials of higher value are already good and likely 
improve. Thus they foresee growing opportunities for the
production of oxygenated hydrocarbons. carboxylic acids,
lipids. sterols, polymeric materials. amino acids etc,
opportunities that will be enhanced now that agricultural raw
materials are to be available in Europe at world prices.
move towards reliance on agricultural feedstocks by the
chemical industry could be compatible with the growing interest
of that industry in specialty chemicals and "effect" chemicals
of higher specific value because agriculture feedstocks can
offer desirable structural features exploitable in the
manufacture of some of these products, for example
plasticisers. surfactants and lubricants.
Areas where biotechnological research is particularly needed in
Europe are reviewed in Table 1. Many of these actions are to be
executed in the framework of the other sub-programmes of the
Biotechnology Action Programme and through special efforts at
Community level to deal with the agricultural surplus problem.
. The activities anticipated for this purpose are outlined in
sub-programmes 1 (Contextual Measures). 2 (Basic Biotechnology)
and through initiatives taken to deal with with the problem of
agricultural surpluses within the Community.
In parallel to the implementation of these sub-programmes and
initiatives. it is suggested to carry out. in the framework of
the Biotechnology Action Programme. projects specifically
designed as contributions to the establishment of efficient
agro-industrial developments within the Community.The objectives are to encourage the development of 
- crop systems for supplying high quality agricultural
feedstocks of European origin to the food. animal feed and
chemical industries. (cf. L. Munck and F. Rexen "Cereal crops
for industrial use in Europe . study contract CEC-I001-B
7210-83 DK, report in preparation).
- bioindustrial processes (both traditional and novel) for the
production of manufactured foods and chemicals derived from
agricultural feedstocks.Improvement of fermentation processes
- new fermentation systems for oils and fats
- development of continuous fermentation for production of
alcohol. beer. wine, or food .additives
- development of control systems for fermentation reactors
with newly designed sensors i2nabling errors to be recognized
and rectified at early stages.
- production of chemicals (special polymers. xanthian gums.
etc.
Use of enzymes (immobilized or otherwise) or of immobilized cells
for
- production of oils and fats
- production of amino acids. pep tides or proteins
- immobilization of lactic acid bacteria producing flavours
and other products
liquefication and processing of raw material
manufacture of alcohol. beer. wine, fruit juices
- elimination of undesirable components (diacetyl,
sulphurous compounds. anthocyanins, flavonoids
during
esters.
. . . )
manufacture of beer. wine.
products
fruit juice. dairy and other
- production of vitamins and antioxidants in combination with
purely chemical syntheses
- production of food additives (colours. flavours, aromas.
stabilizers. thickeners, antimicrobial substances)
Genetic improvement. through mutagenesis or genetic engineering.
of :
- bacteria for transforming dairy products
- yeast for producing alcohol
- yeast for fermenting wine and beer
- microorganisms for producing oils and fat
- microorganis~s for producing amino acids.
proteins
peptides and
- microorganisms for producing food additives
- plant cells in culture f Jr production of lactone flavours. 
food additives, and ?harma~euticals.
Table 1 : possible contributions .of biochemistry, genetics and
biomolecular engineering to the quality. production and
secondary transformation of agro-food (modified from
Biotechnology : a Dutch perspective . STT, May 1981)1.4.
1.4.
The projects t::l be executed in priority order are as
fclluw:3 :
L(  ~h4ological and economic assessment of the use of Eoil
mic~c(:r1!.anisms, agricultural crops. new marine and land
sv~cles, a~d cf new plant parts in order to provide chemical
in,-!.uf"triE's (particularly for fine chemicals and some
s)E:cial tzed oxygenated hydrocarbon products required in
!p'
eat~!r bulk) with agricultural feedstocks of European
orig:~n. The ability must ilc..:easingly be developed to "tune
thecho:~ce of plants flexibly to the downstream needs.
klalysis of the microbial. biochemical, physical and
chemical which regulate the production. procegses
storOlge-life, organoleptic properties and nutritive value of
agro-foods produced through conventional methods in Europe.
To ensure exploitation of results by industries of the
Member States. all contractual research activities for this
project should be carried out by units associating
universities and industrial laboratories. Specific proposals
for research contracts will be formulated by such units and
implemented by them.
Health industry
---------------
An analysis of the causes of foreseeable difficulties for
the European health industries. in particular the
pharmaceutical industries, leads to the conclusion that
Community R&D can play a role in maintaining or improving
the competitiveness of these industries. In this respect.
changing market patterns and financial consequences of
regulatory systems are two of the major parameters which
must be taken into account.
Pharmaceutical screening and tests
... ........... .... ........ ........
European pharmaceutical and biomedically oriented industries
represent a major sector of European economy and employment.
They contribute to export and are still competitive
world-wide. They are however facing several obstacles which
could become very detrimental in the near future. Estimates
of the cost of developing and obtaining approval for a new
drug at present range from 40 to over 100 million ECU. Part
of this cost is due to the long and expensive assessment of pharmacological
activity.
- the examination process to which a drug is submitted
before being registered and marketable.
Therefore. action should be taken along the following lines:
development of new methods for the screening of
pharmacological activity of new molecules.
- development of new methods for toxicological screening in
order to accelerate the present lengthy testing processes.
In this respect, emphasis should be placed on the
development of  in vitro methods which should reduce the cost
of screening and, as they would be developed in common.
would help in providing the basis for common acceptability.
In fact,  in vitro activity tests would improve the chance of
detecting new pharmacological effects. as they allow for
testing separately for specific functional properties
instead of having to rely on the globally integrated results
which are obtained by using whole animals. This approach.
although it cannot be expected to replace current  in vivo
procedures for the final evaluation of effects, may also be
seen as contributing to the design of new drugs (see 4.
below), as it can be extended to the concept of relationship
between body or organ function and structure of the molecule
being tested. At the same time, special efforts must also be
made to develop new  non-invasive in vivo tests which remain
the ultimate objective for clinical diagnosis.
Finally. it is worth mentioning that problems of
confidentiality and intellectual property. normally a
constraint on the scope for Community action in health
industry projects, are less serious in the case of
developing new tests for activity or toxicity : for the
general :i.nterest in their common acceptability
details of the tests to be published.
requires1.4. Health expenditures. and new technologies
..... ......... ..... .... ... ..... ...........
Health expenditures. and most particularly hospitalization
costs, are continuously increasing in Eurape. The burden of
these which costs falls predominantly the state
customer has such consequences on the public purse that
there now an absolute necessity contain, without
hampering the quality or efficiency .of health care, the
casts .of treatment and hospitalization in the Member States.
An essential solutian to this problem may in the long term
be found through the promatian, at Community level, of
techniques, devices or drugs which could contribute to the
prevention of diseases and thus ta the reduction of the
associated costs. National efforts should be integrated and
stimulated particularly in areas where there is need for
long term research and venture investment, for example in
imp raving the present methods .of detecting, preventing and
treating costly diseases. The new technolagies .offer 
arsenal .of approaches far the production of vaccines and
hormones thraugh genetic engineering. the develapment .of new
diagnostic tools (monaclonal antibodies, pratein separati.on
methads...
), 
treatment (antibodies against generally
inactive epitapes, hormones, analogues of newly discovered
neuropeptides, intracellular signal m.olecules... ) and the
preparation of new drugs by computer aided molecular design.
These technologies, which are not sufficiently developed by
industry in the present fragmented state of the market,
should be harnessed for the benefit and interest of
Community of Member States and .of developing countries.
the2. CREATING A FAVOURABLE CONTEXT FOR BIOTECHNOLOGY IN EUROPE
The administrative challenge : the need for concertation
--- ------- - --- ---- ------ ------- --- - ----- - --  ------- - ----
. The development of biotechnology in Europe depends upon the
separate decisions of many independent actors - scientific
researchers. financial investors. corporate managements, final
Consumers - whose individual decisions can be indirectly, but
often decisively, influenced by the actions of the public
authorities. To create a context favourable and encouraging for
the development of biotechnology in Europe demands some
coherence in these actions. This presents the challenge not
only of coherence between the Community and the Member States,
but between separate Ministries and agencies within each State.
and across the services of the Community institutions. For as
Nature s new publication,  Bio/Technology has expressed it,
One the central challenges biotechnology
organizational : it is a boundary-crossing. multidisciplinary,
statistician s nightmare... It challenges the organization of
our universities. our government
statistics and our minds.
" (*)
departments.. our economic
To this challenge, industry has responded by !~orming alliances
and consortial activities (e.g. Biogen, a medium-sized
specialist biotechnology company. owned by a few major
multinational groups) , inter-sectoral and international) .
Within the scientific community. the European Federation of
Biotechnology (founded in 1978) has brought together over 40
learned societies, and industrial participants are prominent in
the specialised. but international, working groups which meet
under its umbrella. In government. many countries have created
ad hoc co-ordinating committees, inter-departmental groups, or
special "missions" to integrate and mobilise national efforts.
(*)
August 1983. p. 526A similar need is felt within the Commission services, for what
is termed concertation of the various activities relevant to
biotechnology : linking horizontally across services within the
Cotmnission. and relating also to the national coordinating
. bodies for biotechnology. to facilitate concertation of
Cotmnunity and Member State actions. Similarly Community actions
have to relate coherently to world developments. be it 
scientific networks, patent conventions or trade agreements.
The need for concerted measures aimed at improving the context
for European biotechnology has been analysed by the FAST
progratmne (*) , which emphasised three "contextual" policy areas
as being of special.importance
the provision to European industries of raw materials of
agricultural origin at competitive prices
- the effective protection .of commercial and intellectual
property rights, on a basis consistent within the ComlIlunity
and equitable in relation to conditions elsewhere in the
world;
the creation of a common regulatory environment (and hence
more truly a common market) within the Community.
These needs, and the corresponding actions, are presented below
(Sections 4. 2 to 4. 4).
In order to identify the necessary actions, to promote timely
initiatives, and to assist concertation between Community and
Member States in matters affecting the development of
biotechnology, it is essential over the next few years to have
a significant capability within the Commission services to
monitor developments and to promote the necessary concertation.
(*) CEC, FAST Programme : Results and Recommendations.
Vole. I & II. December 1982.An essential tool to be used in the improved monitoring
function will be an expanded series of networks. established in
cooperation with the Member States to provide an ad-hoc system
of collaboration between individuals. specialized groups and
. institutions. This will be coupled with an information base.
regularly updated by scanning. selecting. interpreting and
storing in an organized way the incoming .flow of info~ation.
In particular these activities will relate to  the 4 domains
identified by FAST studies as of basic importance for the
future of European biotechnology
Foundation capabilities (human. institutional and other
resources) - strategic strength in biotechnology rests on a
relatively large number of fundamental disciplines and
practical capabilities.
World class capability in all these fields is a realistic
objective for the European Community as a whole. but is
beyond the resources of even the largest Member State. It is
one of the objectives of the basic biotechnology R & 
programme to encourage the competitive emergence of world
class capabilities in all key areas ; it will be one of the
objectives of monitoring and assessment to identify where
weaknesses or new needs are emerging, and to initiate debate
on action required.
Land use - as noted in the Comission' s recent communication
to Council (*) . biotechnology will offer a growing number of
new opportunities for the improvement of agricultural
production. and for increasing the quantity and range of
non-food products (timber. animal feeds. chemicals.
fueL..
) .
There will be increasing interactions between agriculture.
forestry. and the food. chemical. energy and waste
management industries. There is .a need for an integrateej
view of their strategic development. and an integrated
approach to ColIllllunity policies affecting them such
integration will be facilitated br the commitment to
concertation.
(lie)
COM (83) 500Third World relations - biotechnology threatens commodity
1 ,r:)(iu.o:: ers by new possibilities of substitution (e.g.
i'3o(.luc.ose 01: aspartame replacing sugar), but can also
c ont:H.ute significantly to such basic needs as food
?rod~cti~~. storage and improvement. and the fight against
dise.1S';!S which plague man, crops and animals. Whether
througl:. the programme science and technology for
(evelOI mer.t. or trade agreements under the Lollle Convention.
in the self-sufficiency-oriented food strategies now
b~iug Fromoted, biotechnology has many interactions with the
C'.)mmilnl ty Development Policy (*) . The monitoring of these
problems and opportunities, the perception of the
ross-links with the other Community policy areas. will
enhance the prospects for effective anticipatory action.
Health care and pharmaceuticals the pharmaceutical
industry is of importance to all biotechnology for the scale
and significance of its research effort : it represents the
technological leading edge, particularly in the
all-important translation of scientific breakthroughs into
pure, tested, economically produced. marketable products.
Medical research represents another type of leading edge,
and recent advances give hope that acceptable solutions will
be found to many hitherto intractable problems including
inborn genetic errors, malignant diseases and neurological
disorders such as those of old age. Beyond the benefits to
health. these are matters of basic importance for the
competitiveness of Europe industry. for employment. and
for the quality of Europe I s science : touching many issues
of public and Community policy.
In particular. the Commission has to aim. in conjunction
with Member States. at the achievement of a rational
regulatory stance, balancing a conservative concern for
safety against demands for the speedy introduction of new
and more effective treatments. with their putative benefits,
possible risks (See 4. below). and implications for
innovation and competitiveness in one of Europe key
industries
(*)
Memorandum on the Community s development policy : Sept. 1982
(from the Commission to Parliament and Council).Each. of these strategic domains is of course the predominant
concern of a particular ministry (in Member States) or service
(within the Commission) but the rich and proliferating
interactions arising from biotechnology demand a horizontal
. view, if opportunities are to be seized (cf. the fertilisation
of life sciences by information technology : bio-informatics) 
problems avoided (e. g. uncolIlpetitive pricing of raw materials
for the fermentation industry), and coherent policies adopted
(e. g. between promotion of innovation and protection of
established producers or consumers).
Action : the Commission therefore proposes a reinforcement of
its resources for effective assessment (or monitoring) and
concertation of the new and existing activities which bear upon
the 5-year biotechnology action plan. The general objectives
will be to improve standards and capabilities in the life
sciences and biotechnology in the European Community. and to
enhance the strategic effectiveness with which these are
applied to the social and economic objectives of the Community
and its Member States. To achieve these, the following specific
tasks have to be executed. in each case in conj unction with the
relevant services
1. Consideration of how the real value safely and sustainably
derivable from the renewable natural resource systems in
Europe may be maximised ;
2. promoting in co-operation with developing countries and
relevant institutions the pursuit of the same task within
their respective regions
3. consideration of the implications of developments elsewhere
in the world for biotechnology-based industry in Europe.
(For example development of maize-based sweeteners,
chemicals and fuels production in the US has led to greatly
increased offerings of maize gluten feed for animals with
implications for European agriculture, chemicals, SCP
production and Third World trade that require careful
consideration) ;4. identifying opportunities for enhancing through concert at ion
and co-operation the effectiveness of biotechnology-related
programmes in the Member States (e.g. planning the
development of culture collection information services) 
. 5. working with the services of the Community, Member States
and other interested parties to identify ways in which the
contextual conditions of operation for biotechnology in the
Community may be further improved to promote its development
in all useful applications and the supporting scientific
capabilities
6. disseminating knowledge and increasing public awareness of
the nature and potential of biotechnology and the life
sciences. to raise the quality of public debate (of
fundamental long-term importance) ;
7. establishing, in cooperation with Member States, an ad hoc
system of collaborati.on between groups and individuals with
interest and capability the life sciences and
biotechnology so creating a series of networks, as
informal and flexible as possible, adapted to the particular
problems under study.
The networks to have the triple function of providing an
active input into the programme. encouraging coordination
through the exchange of information between the centres. and
assisting the broader diffusion of information envisaged in
task 6.
Provision of raw materials of agricultural origin for industry
--------------------------------------------------------------
Background : raw material needs, evolution and problems of
........... ..... ........... ..... .... ...... ... ....... .....
the current Community regime
.......... ....... ....... ....
Raw materials for biotechnological production originate from
living or fossilized plant life. The principal fossil
resources are coal, natural gas and oil whose price is
determined by energy policy. In order to be used in
fermentation processes fossil hydrocarbons must be converted
into a usable substrate, a typical example of a current
process being methane to methanol which is then fermented
into single cell protein. It is ironic, and instructive to
recall, that the seminal Japanese development work on SCP
from paraffin (another option) was developed in order toenable their fermentation industry switch from
expensive". agricultural substrates to "cheap" imported oil.
The point is that the basic need for a source of carbon
inevitably links these alternative raw materials for
biotechnology. requiring an integrated approach if public
policy decisions in each area are to be coherent with
desired objectives.
The long-term trend of real agricultural prices has been
downwards, over the past 20 years while that for
hydrocarbons has been rising. Consequently the interest of
the fermentation industry has swung predictably back to
agricul ture.
The raw materials derived from agriculture are principally
carbohydrates, that is starch derived from cereals. potatoes
and sugar, either in the pure form or as molasses. For some
processes these raw materials are interchangeable but for
others the degree of purity or the specific nature of the
raw material is essential to the biotechnological process.
These agricultural raw materials are subject to the market
regimes of the C.
For products which find their final outlet in processed
foods this has not led to a loss of competitiveness by the
Community industry since the Community preference
established by the system of import levies and export
refunds is applied equally to raw materials and processed
foodstuffs.
Only a very few non-food products enjoy the protection of
variable components and the system lacks a continuous thread
of basic industrial policy logic.
A few products, such as sorbitol and mannitol, enjoy the
same system as foodstuffs. with both import levies and
export refunds. Other products. such as citric acid, attract
an export refund based on the raw material content but no
variable component is levied on import. This means that for
exports Community industry is on a comparable basis withthird countries but is fully open on the internal market to
competition from imported products made from raw materials
at world prices. Where this competition come!) from EFTA
countries there is no fixed component of duty protection and
for non-EFTA countries the reduction!) resulting from the
Tokyo round are eroding the already low fixed duties.
Where variable components do exist for non-food products
they are not always given for all possible raw materials on
which the process can be based, resulting in further
distortions of the competitive position.
In 1967 (modified in 1975) a special regime was introduced
for starch production which gave a refund for food and non
food starch. The regime attempts to create an equilibrium
between producers using maize. wheat .and potato as a source
material and compensates approximately for the difference in
the price of starch made from raw materials within the
Community and that made from raw materials at world prices.
The level of production refund is decided by the Council and
although adjustments have been made they have not always
kept pace with the gap between Community and world cereal
prices.
A similar system exists for sugar used in producing certain
chemical products.
This refund is directly related in value to the starch
refund but limited to tbe products listed in the annex to
the regulation EEC 1400/78. Again the refund in recent years
gives only a partial compensation for the difference between
world and EC prices.
The cost of producing both existing and new biotechnological
products derived from starch .or sugar is influenced by these
regimes. It is frequently argued that raw material prices
are not a significant proportion of production costs
however, it is marginal costing that will determine the site
of production. and for new investments such as biotechnology
the investment decisions as to the location of new plant
will be influenced by cost factors such as raw materials.It would not be possible to set up for non-food products a .
system similar to that existing for food. .since this would
involve an increase in protection with a consequent
renegotiation within the framework of GATT. which would be
neither desirable nor feasible.
As a policy objective it 
provision of raw materials
necessary ensure the
prices for
which are
world
biotechnological industry making products
unprotected. Such a step will be neutral from a budgetary
point of view. for the following reasons
Where the production of a product from indigenous raW
materials ceases in the Community and is replaced by
imports there is a loss of economic activity and
employment, and the raw material that would have been used
in its manufacture (wheat or sugar) goes into intervention
or is exported with a consequent charge on the budget.
- Where a product is produced from imported raw materials,
such as maize for starch, stopping of Community production
and replacing it by imports of the finished product will
result in a loss of revenue for the Community budget in
the form of import levies on the imported raw material.
Continuing research and development in biotechnology is
giving industry the possibility to manipulate raw materials
and to produce existing products by new methods as well as
new products. It is therefore essential that the regimes for
aw materials for biotechnology offer a free choice at
competitive price level so t!:lat industry can establish a
long term investment policy.
Community action : new regimes on starch and sugar for
... ................ ..... .......... .....................
industrial use
..............
In its Communication on the Common Agricultural Policy 
(*)
the Commission has underlined the necessity lito provide
Community raw materials for biotechnology on the same
conditions of competition as for external competitors
(*) COM(83) 500 Final (2. 10)Th~ ~Qmmission intends to propose to the Council new regimes
tor st.r1ch ar.d sugar for industrial use which will attain
this objective.
A Europea~approach to intellectual property rights in
_. --- ---- .- - - -- ----- -- ------- -- -- ----- - ------ -- -.---- -----
biotachnology
-------------
1 The intellectual property problem in biotechnology
.. ............. ............... ........ ............
The role of intellectual property is to secure the commercial
exploitation of proprietary R & D results in highly competitive
markets and simultaneously to permit the beneficial
dissemination and exchange of knowledge in the field 
activity concerned. Biotechnological R &D and bio-industry are
rapidly evolving and expanding at the international level, and
it is therefore indispensable that the industrial property laws
and instruments available in the Common Market match the need
of science and industry and of the Community s goals.
The option. long used particularly the fermentation
industry. of protection via commercial secrecy, faces major
difficulties in the context of modern biotechnology. The
involvement of multi-disciplinary teams is likely to include
researchers who need to publish or lecture openly to maintain
their reputations witness some of the current
university-industry conflicts, particularly in the U. A. A
greater recourse to commercial secrecy by industry will also
inhibit precisely the pattern of collaborative working which is
needed in this interdisciplinary field if maximum benefit is to
be obtained from individual breakthroughs.
Again, when a micro-organism is involved, an imitator may be
able to achieve industrial replication of the "invention
within hours. and given only a miniscule quantity of material;
unlike other industrial situations where months or years of
effort and investment might be required.
Considerable legislatory work and professional thought has been
devoted, at the international and national level. to enable
h 1intellectual property law. mainly patent law. to cope with the
many specific problems resulting from biotechnological R & D
and industrial microbiology. But the legal situation still
suffers from deficiencies or discrepancies in statute law, and
a general shortage of case law. The problem is worldwide, but
particularly harmful and dangerous to an entity like the
European Community. where the existence of a harmonized and
adequate body law. rules and practices major
importance to the proper functioning of its internal market and
the competitive power of its industries.
The principal issues at stake concern the protection of
intellectual property rights relating to genetically engineered
micro-organisms per set and corresponding problems arising from
the application of such techniques to plant breeding, and
potentially even to animals. The answers to these questions are
of considerable importance not only to certain fundamental
concepts of industrial property, but also to science. industry
and society.
The present legal situation in terms of legal protection is
embarrassing and far from satisfactory. Technology-related
problems that affect everybody are compounded by non-explicit
legislation and poor jurisprudence in and between States and
sharp differences of opinion on future policy within national
administrations, for example between Ministries of Justice and
of Research.
Furthermore Europe has some disadvantages with respect to the
protection of intellectual property rights compared with its
main competitors. the United States and Japan. For example it
is possible to obtain patent protection in the United States up
to one year after publication of the information on which the
patent is based. but in Europe publication. even orally,
precludes subsequent patenting. Again it is possible to patent
new microorganisms as such in both the United States and Japan
but not in Europe.
Both these competitors are taking steps to protect their
national interests concerning biotechnology patents and
inventions. For example concerning the patentability of geneticinventions involving recombinant DNA. the Japan Economic
Journal published the following on 8 April 1980 
The Agency has decided that simple methods to chisel and
refill the ring of any DNA. such as cutting off part of the
. ring and replacing the cut-off chip with that separated from
the ring of a different kind of DNA. will not be patentable
since they are to be considered "well-known" technology.
Also unpatentable will be any "comprehensive kind of idea
covering the whole ambit of the modern gene engineering
processes. "
This appears to prejudge. for Japan at least. the outcome of
the Cohen-Boyer US patent application. which covers basic
processes in genetic engineering.
Despite the lead the US enjoys over Europe with respect to
biotechnology patents, the US Office of Science and Technology
Policy report (cited in 2. 2 above) believes that some problems
remain. It states
The laws and regulations governing patent protection for
biotechnology products and processes are still evolving and as
is the case with emerging technologies. have not kept up with
the rapid pace of development. There are a number of unresolved
issues and questions which could
such
slow the commercial
development biotechnology, the adequacy
international patent protection and the effectiveness of the
Plant Variety Protection Act.
and goes on to make recommendations for extensive review of
current procedures and their impact on innovation. and for
active steps by the U. S. administration to accomplish patent
term restoration (*) and other relevant measures.
Particularly in the field of drugs the average effective life of a
new product has been greatly reduced by the long period needed for
development and for securing regulatory approval. The purpose here
is to extend the terms of patents by the length of time that
regulatory review delayed their marketing.Specific actions at Community level
....... ........ ..... .... ...........
The Commission s analysis of the need had anticipated such
recommendations. and an in-house inter-service group has
been studying the situation of the Community in relation to
intellectual property rights in biotechnoiogy. The aim. is 
identify action priorities and prepare a Community position
on the current and forthcoming challenges. scientific.
technical. economic and political.
A significant factor in the. timing is the OECD study.
launched in February. 1982 : "Biotechnology and government
policies :. Patent protection in biotechnology . The results
of this enquiry. covering practically all of the 24 member
countries (which include all EEC Member States and the major
industrial competitors). should be available by the end of
1983 or early ' 84. They will provide a valuable factual
com.pendium., and will highlight the substantive issues on
which international negotiation will have to follow.
Major unresolved issues include
the patentability of biotechnological inventions as such;
the implications and conditions associated with the rules of
practical protection requirements and procedures (e.g. for
the release of deposited micro-organisms to third parties) 
the addition to the existing problems concerning plant
variety protection. of complex new relations with patent law
(arising, for example. from the new ability to transfer
genetic material between species. or between plant cells and
micro-organisms) .
In order to
- enhance the competitiveness of our industries and the
functioning of the internal market of the EC
- control certain problems specific to biological materials
- assist in preparing a coherent community position in
international negotiations,The follewing e.ctions should undertaken as matters
l rge nc) 
a) th~ Me~b~~ States should be invited to share with the
C~mRission information about the aims and content of ongoing
a~d plaFned work, national and international, regarding the
?rotf'.ction of biotechnological inventions or achievements
e. g. is recently provided in response to the current OECD
enqufry) ;
b) the Coumission should work out proposals to Council for the
resolution of the issues referred to above
c) the Member States and the Commission should seek common
pri~ciples and guidelines for the management and
dissemiuation of biotechnological information and knowledge
arising from publicly financed R & D in biotechnology.
Furthermore, the industrial property issues in biotechnology
re-emphasise the desirability of all Member States ' ratifying
both the European and the Community Patent Conventions, as a
first but necessary step towards a basis for commonly accepted
regulations.
The problem at Community level is that the debate about the
aforementioned issues and their implications takes place mainly
outside the institutional bodies of the Conunumnity, e. g. at the
OECD, WIPO. UPOV (*) and in national industrial property
circles ; hence the reason for the actions proposed under a),
b), c) above. These will have to be implemented by joint
mechanisms of consultation, cooperative studies and concerted
measures, building on the existing practices of Community
coordination and participation in international bodies such as
those mentioned. Only in this way will it be possible to render
industrial property law in the Community fully effective in the
near future and thus support biotechnology research,
development and exploitation in the EEC.
(*) WI PO : World Intellectual Property Organisation
UPOV : Union pour La Protection des Obtentions Vegetales.Concrete actions would be :
i) extension of the Commission inter-service group to an
EEC-national expert group in industrial property matters in
biotechnology for the implementation of actions a) to 
above (say 4 meetings per year. about 20 experts) 
ii) establishment and execution of a programme of studies on
problems concerning the unresolved issues described above
(about 5 to 10 studies in 1984).
A significant obstacle to progress in the rationalisation or
modernisation of patent law in biotechnology is the apparently
acute shortage of patent attorneys with relevant knowledge.
Consequently a further concrete action proposal is
iii) provision of financial aids to European candidates wishing
to enter the patent attorneys ' profession in the field of
biotechnology (since in the training phase. of up to 3
years. the candidates are poorly paid). (On average say 5
candidates per year per member state).
These actions will complement the actions already proposed by
the Commission in ~ransnational infrastructure (1) . utilisation
of R & D (2) and financing of s. e. innovation (3) . which
apply equally to biotechnology.
(1) COM(83) 277
(2) COM(83) 18
(3) COM(83) 241A European approach to regulations affecting biotechnology
----------- -- - -- --------- - ---- ----- --- -------- --- ---  -----
1 Biological safety
.................
Public and parliamentary opinion is divided between admiration
of the new discoveries in biotechnology . and concern about
some of the possible implications or conjectural risks of their
use. This concern reflected the extensive debates,
studies and reports on the need for regulation and control of
various aspects of the life sciences ; a debate vigorously
pursued throughout the developed industrial world. The story of
the initial concern about the conjectural risks of recombinant
DNA ("genetic engineering ) research, the voluntary moratorium
on such research by scientists following the February 1975
Asilomar conference, .the institution of regulatory committees,
and the gradual relaxation of controls as earlier concerns were
reassessed in the light of further information and experiment
(use of disabled strains, physical containment at appropriate
standards) - this story is by now familiar to the general
public, because of the widespread interest and corresponding
newspaper coverage which the topic generated.
Although the perceptions risk have shifted towards
relaxation. public concern remains real ; fuelled in part by
the continued rapid progress of the scientific capabilities and
their application (or applicability) to human germ cells or the
human genome. Current debate also focusses on the field release
of plants modified by molecular genetics. and the possible
risks of large-scale industrial fermentation.
The Parliamentary Assembly of the Council of Europe adopted on
January 1982 recommendations on genetic engineering
(Recommendation 934 (1982)). The Committee of Ministers is
currently considering a feasibility study report relating to
the control of work on the human genome (genetic material)
e.g. genetic screening and gene therapy.
. The OECD through its Committee on Science and Technology
Policy, has instituted a major study of government policy on
the control of biotechnology in its member states. and has
recently distributed a draft report for comment.The World Health Organisation has a professional interest both
in the conjectural hazards of biotechnology (possible risks of
epidemics from the release of pathogenic microorganisms, old or
new). and in its potential .as a production tool
: .
a general
. report is under discussion for publication in 1983
(*)
. Similar
interest has been expressed by the Veterinary section of the
International Office of Animal Diseases.
Specialist administrative bodies and rules have been set up in
the USA (National Institutes of Health Recombinant DNA
Advisory Committee : RAC). in the U.K. (Genetic Manipulation
Advisory Group : GMAG), and in many other countries. often
adopting the approach (registration. containment standards for
various categories of experiment) of NIH or GMAG. The policy
debate in the U.S. continues to be vigorous. The NIH/RAC is
currently considering authorizing the release into the field of
manipulated plants. Various Congressmen (Gore. Kennedy) are
preparing legislative proposals. As with the Council of Europe
study cited above, attention is focussing increasingly on
issues of human genetic screening and (more remotely) possible
interference with the human ge~ome
Industrialists - particularly in the pharmaceutical industry in
the first instance - are concerned about the prospect of
excessive restriction limiting their scope in research and
hence their competitiveness : Sweden. the Netherlands and Japan
were countries felt by some of their industrialists to have
adopted an excessively conservative position on rDNA work. to
the detriment of their biotechnology. and to have been slow in
following the consensus for relaxation. In the Safety in
Biotechnology Working Group of the European Federation of
Biotechnology, industrialists and academic researchers have
joined to draft recommended guiding principles.
There has been corresponding activity and interest in the
Community institutions : numerous questions have been asked in
the European Parliament, and in May 1981 the Economic and
Social Committee held a colloquium in Brussels on safety in the
field of recombinant DNA.
(*) WHO regional office for Europe : ICP/RCE 602(1) (S)
Summary Report of the Working Group on the consequences of
biotechnology on health. 6. 83.The C,)\r..lcil adopted on 30 June 1982 a recommendation on the
p'.
oble~1lf, 'iJising in safety related to recombinant DNA work.
Ther~ ar~ three main areas of risk:
- ifi the research laboratory
- in ift~ust rial production
- at the stage of marketing (free circulation of goods).
These are discuRse:l terms technical and regulatory
aspects in the sections 4. 2. 4. 3 to 4. 5 below.
Given the continued level of widespread public and political
concern, r,,"-flected in the many fora mentioned, and in the
similarly persistent concern with issues such as animal welfare
and their use in tests, which also impinge on biotechnology, it
clearly necessary for the Commission maintain
awareness of the social dimensions of biotechnology and the
interfaces with the various policy areas on which these
dimensions impinge.
In terms of concrete action, the Commission s FAST programme
launched a "Social Dimensions of Biotechnology
multi-disciplinary working group. drawing on industrialists,
risk analysts. a philosopher of science and academics. This
group, which met sporadically over 1980-82. produced a short
report (incomplete, through shortage of staff and resources).
offering 5 general "principles" which should guide public (and
Community) policy in the "management of our bio-society
" :
1. There can be no policy of zero risk.
2. There are limits to the competence of experts.
3. Even within these limits, their credibility/acceptability is
questioned.
4. There is a need for adaptive strategic management, taking
account of long-term. "total system" effects so far as
currently perceivable. and accepting that perceptions will
be modified by experience.
5. There is a need for continuing education at many levels.
including decision-makers. the general public and the
scientists themselves.
':;0Action : in order to maintain awaren~ss of ~volving pressur~s
for n~w policies or regulations, a  monitorin~ function is
needed. at least to collate at Community lev~l the evolving
views of national regulatory bodies. Of the 5 "principles
cited above. items 4 and 5 could in part be combined with this
monitoring
appropriate
role. i. e. assessing developments. and where
assisting the production and diffusion
objective, factual information
area
(cL the
) . 
This
Commission Y S two
earlier reports this function can
appropriately combined with the concertation role described in
1 above. and provision for it is included in the budget
estimates (section 5.3).
2 Food innovation : industry, consumer and regulator
... ...... ... .................. ........... .... ......
Of the "social dimensions" of biotechnology, its impact on feed
and food has also given rise to significant debate : witness
the acceptance problems some countries single-cell
protein (SCP).
The supply, processing and storage of food and drink has for
millennia been almost synonymous with biotechnology in the
traditional sense the term. The r~cent scientific and
technological advances offer the prospect for continuing
innovation and improvement
in production efficiency, in tastes and flavours, and in
functional aspects such as storage, convenience, consistency,
nutritional standards and safety. Continued progress in all
these respects is essential for the competitiveness of Europe r s
agro-food industry, and must be directed towards the benefit
and satisfaction of the consumer.
That the consumer is willing to accept innovation is readily
illustrated : in deep frozen foods. in the explosive growth of
yogurt sales, or in the all-too-ready displacement of native
cereals by imported wheat in many Third World cities.
(*) Sargeant , K. and Evans. C. T. : Hazards involved in the
industrial use of micro-organisms. EUR 6349 EN.
Evans, C. T., Preece, T.F. and Sargeant, K. Microbial pathogens : natural spread, and possible risks in their
use.
plant
industrialOn the other hand. textured vegetable protein. scientifically
logical from the standpoint of cheap nutrition or global land
use, has achieved only limited success as a meat replacer or
extender : illustrating not only a need for further technical
development by the food biotechnologist, but deeper aspects of
consumer psychology in attitudes towards. and perceptions of.
their food. The strength of such feelings is evidenced by the
many religious restrictions food and its processing
restrictions possibly originating in well-founded pragmatism
related to health risks ; or historical social relationships.
Debate on food innovation is therefore typically a complex
mixture of food science and human psychology ; of concern about
real risks to health, jostling with concern about real risks to
market share. Examples are legion the battles between
margarine and butter ; between single-cell protein. and soya
between "natural"
, "
nature-identical" and "synthetic
The roles of the public authorities, at both Community and
Member State level, impinge several points upon the
agro-food industry and the consumer : encouraging innovation,
harmonizing regulatory regimes create genuine common
market, and ensuring that regulations are based on rational
assessment and well-informed debate ; while seeking always to
maintain high standards of nutrition and safety. It 
essential to maintain public confidence in the independence and
integrity of the Commission and Member States as regulatory
bodies. The challenge of new biotechnology cannot be met by
suppressing innovation but the maintenance of a balanced
regulatory stance. and the management of the long-term societal
learning process which determines this stance. demand
reinforcement or extension of public policy in three areas
the maintenance of high scientific capabilities in public
sector agencies, research institutes or universities.
clear independence from commercial interests
public information (or education, in the widest sense)
ensure informed debate
the reinforcement of administrative capacities at the
relevant levels (number and quali ty staff) that
inadequacies or shortages do not constitute a bottleneck or
a distorting factor in the control of innovation.Action : as with the previous section on rDNA and the human
genome, the need is to maintain in the Commission the staff and
skills to monitor .and anticipate developments in the situation,
and concert necessary policy discussions and initiatives across
. the services, with Member States.
groups (e.g. consumer associations).
and with other relevant
3 Laboratory Research
...................
Excluding defence research, pathogenic micro-organisms have
long been used in certain specialized research laboratories and
accidents are rare (e.g. smallpox Birmingham 1981). The risks
are limited above all by the competent methods of work and
precautions taken by the research workers. rather than by
detailed regulation.
In the field of genetic engineering the Council Recommendation
of 30 June 1982 envisages
the registration by the competent authority in each Member
State of every laboratory using recombinant DNA;
the notification of protective measures and controls
a description of the programme of research which enables the
risk to be evaluated.
4 Industrial Processes
....................
The risks represented by fermentation volumes from one thousand
to one million litres are considerably larger than those
encountered in research. These affect workers. the immediate
surroundings of the plant and also the whole of the population.
In contrast to chemical or radioactive pollution which can be
normally limited, micro-organisms can propagate over large
areas. The problem has already been encountered in the
manufacture of live vaccines and other traditional
fermentations. The approach is to use "invalid" micro-organisms
which are not capable of developing freely outside their
enclosed environment. Successive levels of biological and
physical containment are laid down in some countries.As a first a?proach the Directive 80/1107/EEC of 27. 11. 1980 on
tet 1')':0  :e:tion of workers against the risks from exposure to
~hem:L~~l J ph/sical and biological agents should be examined to
see if iL si~as adequate cover.
The c. hOl~ gl:0UP of the OECD fixed in December 1982 has a
~riority task in view of international harmonisation to
ideI~t ify  small lJumber of DNA groups. particularly those
ccming bon plasm:..ds which ar.! c.lready widely used in research.
end which ~ould not cause added risks if they were subjected to
auto-~loaing. This V'ork . could lead to the establishment of a
list of concrete examples of DNA groups for which recombination
could be authorized in industrial production.
5 The Regulation of Products and their free Circulation
................................... ...... ........ ....
The bio-industries, given the high entry costs and long time
scales (for both R & D work, and regulatory approval), have
great need of the full dimensions of the European. and indeed
the world, market for their products or innovative processes
which require these dimensions and long periods of time in
order to achieve profitability and justify their investments.
They will be unable to develop satisfactorily in Europe if
their activities or access to markets are blocked by divergent
national standards, particularly in the health regulations of
the Membe.r States ; e.g. obligations to repeat identical or
similar tests in each country. Regulations. while they have to
be drafted leaving some flexibility for interpretation as new
situations arise. need also to be clear enough to provide a
basis of confidence for industrial commitments.
In order to avoid new problems in the functioning of the
Community internal market. the Commission has undertaken
consultation with committees of government experts and with its
own expert scientific committees in various sectors touched by
biotechnology such as pharmaceuticals. chemicals, human
nutrition. animal feedstuffs etc.From a first review of the situation. it would appear that the
application of current Community regulations (*) in the various
fields will meet current regulatory needs. provided that there
is close cooperation between the competent authorities in the
Member States and the Commission. Such cooperation can be
achieved by greater recourse to the existing institutional or
scientific committees and. as necessary. use of the new
information procedure for technical standards and regulations
adopted by Council in its directive 83/189/EEC of 28th March
1983.
On the basis of its experience deriving from the use of these
various instruments. the Commission will put forward general or
specific proposals appropriate to create a regulatory framework
suitable for the development of the activities of the
bioindustries and for the free circulation of goods produced by
biotechnology. In its proposals. the Commission will be careful
to introduce at Community level measUres meeting urgent needs.
and pursuing the common interest in line with Article 36 of the
EEC Treaty.
(*) See in particular
- pharmaceuticals : directives 65/65/EEC. 75/318/EEC. 75/319/EEC.
78/25/EEC
- veterinary medicines : directives 81/85/EEC and 81/852/EEC
- dangerous chemical substances : directive 79/831/EEC
- food additives : recommendation 80/1089/EEC
- bioproteins for animals : directive 82/471/EECRETURNS TO BE EXPECTED FROM THE PROPOSED ACTIONS
From training and research
------------- -------------
1.1. Benefits from "horizontal" actions : training and mobility of
.. .............. ....... ............. ... ................ ......
scientists
..........
Although returns cannot be expressed in financial terms. it
is obvious that considerable benefits to biotechnological
R&D in Europe may result from the portion of the programme
which prt)vides for training action specifically adapted to
the requirements of research in basic biotechnology. Basic
biotechnology is a multidisciplinary branch. not normally
taught in universities. The best experts who are able to
teach specific aspects biotechnology are scattered
throughout the Community in laboratories of high scientific
level. In addition, there is an urgent need to increase the
mobility of European scientists who are often reluctant to
speak any other language than their own or to remain outside
their home countries for extended periods. Finally, one must
also break the barriers which many cases isolate
industries from universities and prevent the flow
information between basic and applied research. The training
actions foreseen in the sub-programme are focussed upon the
improvement of scientific capabilities through the transfer
of information and skills
- between disciplines
- between public and private laboratories
- between Member States.
1.2 Benefits from "horizontal" actions : basic biotechnology and
.... .................. ............ ...... ...... ......... .....
contextual R & D
................
It is practically impossible to predict the outcome of an
action, half-way between fundamental and applied research,
of the type foreseen in the framework of this programme.
Indeed it is the unpredictability of research which creates
a problem of scale and choice. since it is difficult even
for large organisations or countries to pursue all the
potentially promising lines of enquiry. As C. de Duve puts
it, " .. research is an essentially open-ended adventure.1.3
where the unusual or unexpected may quite possibly be of
greater interest than what was planned. ...
The pathways through which fundamental discoveries lead to
social or economic returns are so complex, even with the
benefit of historical hindsight. that an accurate
cost-benefit assessment is hardly possible ; still less so
for future prediction. But the European scale gives the
opportunity to pursue a wider range of options. more
effectively than if each country sought to spread its
resources over all possibilities. Through participation in
joint Community programmes. the emergence of strong teams
and centres of specialist expertise will be encouraged, and
the benefits of these strong centres will be available to
the whole Community.
Notwithstanding the problem of prediction in these
horizontal" actions. it is to be expected that the
specific" actions should contribute significantly to the
Community at several different levels the following
sections assess these.
Benefits from "specific" research actions : Increased added
........ ...... ................ .............. .... .... .......
value of agricultural production
....... ...... ...... ... ..........
The advances anticipated in the programme through genetic
engineering can be expected to lead to the production of
plants with novel value as industrial feedstocks or with
increased qualities such as high protein content. resistance
to important diseases. improved symbiotic relationships with
microorganisms in the soil. It is not possible, in view of
the diversity of possible applications. to make any precise
estimate of expected returns which. in some cases, could be
considerable. For instance, the improvement of Rhizobium
strains by conventional selection methods in the USA has
been estimated to allow a net return in savings and
productivity corresponding to $ 2 billions. Genetic methods
are now being developed by Japanese scientists. which can
apparently increase by a factor of 3.5 the nitrogen fixing
efficiency of bacteria which grow symbiotically with rice.
Research of this kind on certain stocks of wheat which are
claimed to grow symbiotically with nitrogen fixing bacteria1.4
CQulc;1. lead. successful, substantial economies
f;~:tt ~li:t.e-r requj.rement.s. Many examples of this type exist
and ..:.llal,trate the importance of possible benefits to be
dt!rived for European agriculture and for European
tT.ansformation industries from long term research in genetic
en~ineer~n& and on the molecular biology of cultivated
plaDt'3.
Tile scaLe of potential benefits is indicated by estimates of
the ~iz~ of the world market for agro-food products. and the
growing proportion of these produced by biotechnological
convers: ons.
The sales of the 25 largest European agro-food industries
are of the order of 70. 000 MUC. Products manufactured by
biotechnological means account for 15% of overall sales.
According to Bioconsult (Biofutur, 1982 . 8. 40-43) from 1980
to 1990, the world market for biotechnological products will
increase by 3. 000 MUC for agro-food and by 10. 000 MUC for
chemicals.
Other market estimates for "biotechnology" (undefined) were
quoted in section 1. 2. (Market potential) : e.g. the T.
Sheets estimates for year 2000 of ~ 12. bn for new
foodstuffs, ~ 10.5 bn for industrial chemicals. But these
are relatively small numbers. and subject to great
uncertainty. The important point is that to maintain the
competitiveness of the whole of European agro-food
production. the entire sector must have available to it the
best available technology. A farmer s expenditure on seeds
may be a small proportion of his total costs ; but if he did
not buy them, or bought inadequate ones, all his other
efforts and expenditure would be wasted.
Benefits from "specific" research actions development of
............... ... ...... ........... ........... ........ .....
new methods for the production of pharmaceuticals. new
.............. ..... ...... .... ........ ......... ........
medical technologies. screening and tests
.... ...... .... ..... ............... .......
Here also. the long term consequences of research in basic
biotechnology appear to be attractive in all areas dealing
with the production of pharmaceutical and medical compounds.
For instance. and to state only some specific examples of
successful achievements among many others, the world marketfor some of the reagents currently used for blood grouping
is presently estimated at about $ 17-18 millions. These
reagents contain small amounts of unwanted antibodies which
cannot be removed during processing. Newly introduced
monoclonal antibodies can now be used. in replacement of the
conventional reagents. which completely eliminate these
impurities. There is little doubt that many other markets
will open their doors to monoclonals. particularly for
diagnosing diseases. if proper mission oriented research is
conducted in this area. The possibilities for production of
certain high added value compounds (human vaccines, insulin,
interferon, growth hormones
...
) are so well known and so
enormous that there is no need to consider them in the
present framework. Their potential market value is such that
the research requiremen ts are adequately covered
industries in the Western world. Such a conclusion does not
entirely apply processes and substances (dyes, food
additives. vaccines for farm animals) of smaller importance
and for which industrial involvement is less pronounced.
Market values can nevertheless be considerable and a recent
estimate indicates. for instance, that the vaccine just
developed against "blue tongue . a disease in sheep and
cattle. may save $ 30 million per year to the US livestock
industry. Similar returns are to be expected elsewhere in
animal disease control.
The development, as foreseen in the present programme, of
new medical technologies for the prevention or rapid
treatment of common and costly diseases could lead to
substantial reductions in the cost of medical care
(particularly hospitalization), at least for those specific
diseases (cf. polio. smallpox. tuberculosis). At present,
major (social) costs result from influenza major
hospitalisation and social costs are associated with heart
disease. cancer. and diseases with significant auto-immune
components (e.g. arthritis) ; major hospital/institutional
costs are associated with geriatric care (senile dementia.
incontinence, Alzheimer s disease. arthritis). On almost all
the diseases mentioned. there are significant possibilities
for progress based on
monoclonal antibodies)
the molecular approaches (e.g.
of the "second pharmaceuticalrevolution . The annual savings which could result from a
decrease of only 1 % of health expenses in the Member States
amount to 800 MUC.
In the medium term. production costs of drugs and new
compounds should benefit from the partial replacement of
present  vivo testing methods by  in vitro screening
techniques. which are also likely to be more informative.
Creation of conditions favourable for biotechnology
---- --- ----- - - - - --- - - -- - - - ------ - - ------ ----- - -- ---
1 Benefits from providing competitively-priced raw materials
..... .... ....... .......................... ................
from Community agriculture to industry
... ..... .... .................. ........
The above measures will stimulate increased consumption of. and
addition value to, Co1IIDiunity grown raw materials
particularly in the food, timber, paper, chemicals and
pharmaceuticals industries. At the same time, new opportunities
will created for investment, increased employment, and
improvement in the balance of trade.
The first benefit will be a better use of land in the Community
through more efficient production of existing crops and through
the development of new crops that better meet Community needs
for food, feed, industrial feedstocks and, to some extent,
energy. By encouraging the industries involved to work together
in a more coherent manner the overall value added by their
efforts will be increased. Agricultural surpluses will be
reduced and employment in these industries will grow.
In the chemical industry increased use of Community
agricultural products will tend to enhance the control the
industry has over its feedstocks (as compared with current
dependence on Middle East hydrocarbons). and encourage the
development of special effect chemicals of high specific value
by exploiting the structural diversity of agricultural
products. The ability to exploit this diversity will be
reinforced by the plant genetic and bio-processing projects
already cited.2 Benefits from a coordinated Community approach on intellectual
........................ .................................. ....
property rights and regulatoryharmonisation
.... ...... ..... ..,. ...... .......... ,...... ...
The contextual measures to be taken in respect of intellectual
property rights and regulations will encourage the industries
mentioned to build their futures on the larger and more secure
base offered by the Community market rather than on individual
national bases. thereby also offering a more substantial base
from which to address the world market.
international trade negotiations and standard and
familiar economics, the market 350 million relatively
well-to- consumers basis for both wealth through
internal free trade, and political strength. The- argument is
sufficiently well known to require little repetition in a
community document : in the context of a technology touching
such sensitive issues as agriculture, food, medicine, health
care and education. it is no less relevant.
3 Benefits from assessment, concertation and networks
.'.... ... ....... .......... .... ...... .... ... .... ....
Emphasi~ has been placed (4. 1) on assessment, concertation.
networks and administrative reinforcement as necessary to
biotechnology. This emphasis
with which
the
based
the Community
challenge of
enhance the strategic effe.ctiveness
and the Member States respond
extensive and
disappointing experience of the difficulty of mobilising and
concerting the movement of a large number of public agencies or
departments. typically heavily occupied with day-to-day
responsibilities, to respond to a cross-cutting and long-term
challenge.
Perception of emerging strategic needs or problems originates
with knowledgeable or far-sighted individuals. Their claims and
predictions have to be filtered from competing. alternative
claims : evidence has to be gathered. hypotheses formulated and
tested ; jf significant resources are required, those Vlho
command the resources have to be persuaded - first of all to
listen. then to be willing to act ; finally plans for hOVl to
act have to be formulated. Thus the essence of  strategicpolicy analysis function combination perception,
listening, testing. analysis, persuasion and communication.
Failures policy analysis result in technological
wasted resources, loss of market share. and backwardness,
economic dependence and weakness. It would be easy - with the
benefit of hindsight to quote examples of neglect or
misj udgement, from microbiology to monoclonal antibodies
science policy advisers in every country can identify their
own. In companies, the response may be livelier. the penalties
for failure sharper - but company action may be limited by
factors outside their control. including factors within the
control of government or Community institutions ; and company
lobbying of government may be viewed as pleading a sectional
interest.
In conclusion, the apparently unproductive activities of
listening and learning, thinking and checking, talking and
persuading may yield at least as high a strategic return as any
scientific breakthrough in itself. Such is the logic used in
Japan, first for the creation of the Committee for the
Promotion of the Life Sciences (1973). and more recently in the
creation of MITI' s ' Bio-Industry Office' (June 1982). In the
more complex structure of the Community and its Member States
and their respective service units and agencies, the need for
timely assessment, concertation and communication in policy for
the life sciences and biotechnology is at least as great.RESOURCE REQUIREMENTS
RESEARCH AND TRAINING
DEMONSTRATION PROJECTS
CREATING THE CONTEXT : CONCERTATION AND ADMINISTRATIVE ACTION
Table 5. 3. : Estimate of the Total Budget, 1984-RESOURCE REQUIREMENTS
Th( mobilisation programme outlined in this communication
re~ui  res  a combination of measures and actions, di ffering widely in
th~ir I'ature,. resource requirements and timing. In spite of
t'1i" ;iv~rsi ty, they must be seen as elements of a coherent
ov;::rall approat;h, althOllgh for administrative and legal
"'e. ~so'1S the el.~ments may have to be .presented and considered
separately for decision.
In re~a~on to the major strategic objectives of the pro-
gramme, som.e mdY consider the scale of resources discussed
below deri sory : less than a tenth of the sca le of a typi ca l
pharmaceutical company s R & D budget, .and far from closing
the one-hundred-mi II i on-do lla r- a. gap between Communi 
and U. S. pubLic sector R & D effort in biotechnology
(documented in COM(83)328/2, the background note presented
at Stuttgart).
Again, it may be asked why biotechnology, of more pervasive
and fundamenta L signi fi cance even than information technology,
calls for resources only Oh the scale proposed.
But such comparisons would not be apt : for the essential
feature of this programme is to  catalyse greater effectiveness
in the resources already being deployed, by Europe s companies,
and by the Community Member States in thei r national pro-
grammes for biotechnology.
This approach recognises Europe s existing and potential
strengths in biotechnology; and by focussing selectiveLy
on points where that potential is not being realised, aims
to achieve multiplier effects far beyond the scale of
expendi ture proposed.
The Commission proposes in order to reach the objectives
out1ined in chapter 4, the reinforcement of existing
structures and programmes and the launching of new actions
presented below under the follow~ng head'ngs :Research and training
Demonstration projects
Creati ng the context : concertati on and.
administrative action
RESEARCH AND TRAINING
Most of the projects outlined in the present proposal
cover R & D activities which need to be launched or stimulated
within the Community. It is thus by indirect action, imple-
mented through cost-shared contracts with laboratories
(private or public) in the Member States, that the greatest
part of the programme must be executed. The only excepti ons
are certain elements of sub-programme 1 (contextuaL measures
for R & D) which are to be implemented t~rough studies
workshops and participation in activities with non-member
countries. Such participation will take place
- in the framework of the COST programme
- in supporting activities for the international networks
relating to the theme "Technology, Employment and Growth" which
resulted from the Versailles Summit in 19R2
- in other international contexts relating to global infra-
structure developments (e.g. information, gene ~ollections)
wherever it is advantageous to adapt European initiatives
to worldwide systems.
The methods used for evaluating budgetary needs and 
requi re-
ments in staff wi II be presented in detai  in the programme
proposal for Community R .& !) in Biotechnology whi eh the
Commission is now preparing. Essentially, the scale of effort
requi red in each area has been based on the need to create
multi-disciplinary teams of operationally effective but
manageable scale, drawing on the ~dvi ce of experienced
academi c and industrial researchers.
(Seeo  for example, the analysis and calculations by C. de !)uve*).
(1t)  C. de Duve
, "
Cellular and molecular biology of the
pathological  state a proposal for a Community Programme
in 8iopathOlogy", Dot. fUR 6348, 1979.Requi reme.nts in Commission staff have been assessed by
taking into consideration the diversity and breadth of the
fields covered by the proposal, which will demand  expertise
f,.om scientists of correspondingly diverse background, and
a number of distinct administrative bodies and systems of
procedure.
Table 5.1 : Tentative Cost Breakdown for the R &0 Elements
of the Biotechnology Action Plan
(3) Management Contracts Tota l Staff
Contextua l
measures (R & 0) 1.87 12.
Basi c
(1) 10tec no ogy 1.21 35 . 37.
20. 21.
30. 32.
Agro-food
Hea lth Industry
Coordination with
(2) non-Member States 1.50 1.50
Administrative support
94. 106.
----- ----- ------ ------ ------ ------
Notes : (1) to start on 1. 1986, immediately after completion
of the present Biomolecular Engineeri ng Programme.
(2) includes two COST actions and participation in the
networks resulting from "Technology, Growth and
Employment" created at the Versai lles Summi t of 1982.
(3) includes cost-shared research contracts, training
contracts and study contracts.At some 21 Mio Eeu per year, the above action would add
approximately 6% to the 355 Mio EeU currently bei ng spent
e*) through Member States
Nevertheless, the budgets proposed for each of the R & D
activities outlined in chapter 4 are of a size suffi dent for
the execution of significant research, because they will 
focussed on the selected areas.
The selection has been targetted, as explained in chapter 4
where
- the structures and context needed at European level for a
successful development of bio-industry are obviously
lacki ng;
- there are signi fi cant gaps or weaknesses in the programmes
for biotechnological R & D presently executed in the Member
States.
An intangible but re.al benefit is the adDitional
, "
catalytic
dimension which derives from a well-executed and administered
Community R & I) programme, of which there are aLready several
well-known examples.
DEMONSTRATION PROJECTS
In addition it is the intention of the Commission to complement
as nece.ssary the R & D activities in biotechnology, 
by  demonstra-
tion projects, designed to faci litate the transition between
research developments .and fulL scaLe expLoitation on a commer-
ciaL basis. The budget needed for demonstration projects wilL
be framed to relate also to the other Community actions
bearing on the implementation of biotechnology - e.g. from
other research programmes $uchas Energy, Environment , Raw
Materials, Basic TechnologicaL, or Agricultural. The scaLe,
status and timing will be specified at the appropriate stage.
(*) Doc. COM(83)328/2Evidently it is impossible to anticipate the outcome
of research with a precision sufficient for costing demons-
tration projects; but a realistic order of magnitude would
be between 10 and .20 Mi.o ECU p.a. - say 80 Mio ECU over
the5-year period.
CREATING THE CONTEXT : CONCERTATION AND ADMINISTRATIVE ACTION
As described in section 4. 2 the actions proposed by the
Commi ssionfor the establ i shment of a proper background
for bi otechno logy in the Community i nc lude 
(a) reinforced  assessment and concertation for biotechnoLogy..
as outlined in 4. 1: within the Commission services,
between Communi ty and Member State level, and wi th the
wider international context;
(b) provision of  raw materials of agricultural origin for
industry (4.
(c) reinforcement of preparatory work to negotiate
improvements in  intelle~tual property rights (4. 3);
(d) reinforcement of European approaches to  regulations affec-
ti n9 biotechnology (4. 4) .
The assessment of budgetary needs (including staff requi rements)
is difficult to make because existing structures wi II in every
case be used to the maximum to contribute to the programme
objecti ves. But it would be illusory to suppose that current
staff are sufficient to undertake the additional role demanded
if the Community is to respond effectiveLy to the challenges
of bi otechno logy.
Detai led budgets have been prepared for two of the key eLements
. the programme out Li ned i n chapter 4 :(a) the reinforcement of assessment and conc~rtation,
the operation of the networks, and the related context-
oriented (non-R8.D) tasks outlined in 4. 1 : 6..6 Mio ECU
(see Table 5.2);
Table 5.2 : Tentative Cost Breakdown for the Monitoring
Concertation and Contextual (non-R 8. D) Elements
of the Biotechnology Action Plan
Budget
Headings Mio ECU
Staff (8)
Missions
Meet i ngs
Studi es
Di ffusion
and
Communi cations
(*)
Total
(*) i ndudi n9 parti cularly network communi cations, computer
conferenci ng, :and support for the production of publications,
audio-visual mater; als and other means as appropriate
(b) the special studies and working group activities relating
to commercial and intellectual property, as outlined
in 4. 3 : expert group (0. 1 Mio ECU, 1984 only);
studie~ programme (0. 5 Mio ECU, 19~4 only); training of
patent ..ttorneys (1.8 Mio ECU, :5  years)  : total 2. 4 Mio ECU.In drawing together in Table 50 3 below the diverse estimates
pr.esented above, the intention is to give an indicative
over~ll figure for the scale of resources which wi II be
requested by the Commission in the individual proposals
for decision which will follow this communication.
Table 5.3 : Estimate of the total budget needed by the
Commission for implementation of its
biotechnology action plan during
the period July ' 84 - June 1
Mio fCU
Research and training
Demonstration projects
Contextual actions (concertation, intelLectual
property, ...
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Other administrative reinforcement, e.g. studies
and i nvesti gati on$ re lated to rei nforcement
of regulatory coordination; modifi cation of
agricultural price or market regimes;
reinforcement of biotechnology in Community
Development Policy : say 1 Mia ECU p. a. for
5 yea rs .... & . . . . . 0 .0 . . . . . . . . . . 
. . . . . . . . . . . .
Provisional order-of-magnitude total 200
---
(40 Mio ECU p.